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 Many patients seek genetic testing to see if 
they have mutations in their genes that are 
associated with a significantly increased risk of 
breast or ovarian cancer.  Respondent Myriad 
Genetics obtained patents on two human genes that 
correlate to this risk, known as BRCA1 and BRCA2.  
These patents claim every naturally-­occurring 
version of those genes, including mutations, on the 
theory that Myriad invented something patent-­
eligible simply by removiQJ ´LVRODWLQJµ WKH JHQHV
from the body.  Petitioners are primarily medical 
professionals who regularly use routine, conventional 
genetic testing methods to examine genes, but are 
prohibited from examining the human genes that 
Myriad claims to own.   
The question presented is:  Are human genes 
patentable? 
LIST OF PARTIES 
 The petitioners are the Association for 
Molecular Pathology, American College of Medical 
Genetics and Genomics, American Society for 
Clinical Pathology, College of American Pathologists, 
Haig Kazazian, MD, Arupa Ganguly, PhD, Wendy 
Chung, MD, PhD, Harry Ostrer, MD, David 
Ledbetter, PhD, Stephen Warren, PhD, Ellen 
Matloff, M.S., Elsa Reich, M.S., Breast Cancer 
$FWLRQ %RVWRQ :RPHQ·V +HDOWK %RRN &ROOHFWLYH, 
Lisbeth Ceriani, Runi Limary, Genae Girard, Patrice 
Fortune, Vicky Thomason, and Kathleen Raker.  The 
respondents are Myriad Genetics, Inc., and in their 
official capacity as directors of the University of Utah 
Research Foundation, Lorris Betz, Roger Boyer, Jack 
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Brittain, Arnold B. Combe, Raymond Gesteland, 
James U. Jensen, John Kendall Morris, Thomas 
Parks, David W. Pershing, and Michael K. Young.  
The United States Patent and Trademark Office 
(PTO) was dismissed as a defendant by the district 
court and that ruling was not appealed.  Accordingly, 
the PTO is not a respondent here. 
RULE 29.6 CORPORATE DISCLOSURE 
STATEMENT 
Petitioners do not have any parent 
corporations, and no publicly held company owns 10 
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OPINIONS AND ORDERS BELOW 
The order of this Court granting certiorari is 
reported at 133 S. Ct. 694 (2012).  The opinion of the 
U.S. Court of Appeals for the Federal Circuit 
following remand from this Court is reported at 689 
F.3d 1303 (Fed. Cir. 2012) (Pet. App. 2a-­119a).  This 
&RXUW·V RUGHU JUDQWLQJ FHUWiorari, vacating, and 
remanding in light of Mayo Collaborative Services v. 
Prometheus Laboratories, Inc. is reported at 132 S. 
&W3HW$SSD7KH)HGHUDO&LUFXLW·V
original decision is reported at 653 F.3d 1329 (Fed. 
Cir. 2011) (Pet. App. 120a-­231a).  The district court 
opinion granting summary judgment to Petitioners 
and denying summary judgment to Respondents is 
reported at 702 F. Supp. 2d 181 (S.D.N.Y. 2010) (Pet. 
App. 232a-­357a).  An earlier opinion of the district 
court denying the motion to dismiss based, in part, 
on standing is reported at 669 F. Supp. 2d 365 
(S.D.N.Y. 2009) (Pet. App. 358a-­425a). 
JURISDICTIONAL STATEMENT 
 7KH )HGHUDO &LUFXLW·V GHFLVLRQ LQ WKLV FDVH
following remand was issued on August 16, 2012, 
and this Court granted a timely petition for certiorari 
on November 30, 2012.  Jurisdiction is conferred by 
28 U.S.C. § 1254(1). 
STATUTORY PROVISION 
35 U.S.C. § 101 SURYLGHV´:KRHYHULQYHQWVRU
discovers any new and useful process, machine, 
manufacture, or composition of matter, or any new 
and useful improvement thereof, may obtain a patent 





Human genes are, of course, products of 
nature.  Genetic variants, including mutations, are 
also products of nature.  How genes work and 
whether variants are harmful or not are laws of 
nature.  Respondents Myriad Genetics et al. did not 
invent any genes or variants or cause their 
significance, but they did obtain patent claims on two 
naturally-­occurring human genes known as BRCA1 
and BRCA2 (so named because one of the diseases to 
which the genes are linked is breast cancer).  The 
claims are not limited to any form, variation, or 
structure of the BRCA1 or BRCA2 genes, and they 
cover the BRCA genes of every person in the United 
States, even genes that Myriad has never seen.   
Myriad defends its claims on the grounds that 
a gene becomes a human invention when removed 
IURP WKH KXPDQ ERG\ ´LVRODWHGµ  8QGHU WKLV
UDWLRQDOHDNLGQH\´LVRODWHGµIURPWKHERG\ZRXOGEH
SDWHQWDEOH JROG ´LVRODWHGµ IURP D stream would be 
SDWHQWDEOHDQGOHDYHV´LVRODWHGµIURPWUHHVZRXOGEH
patentable.  This defense defies common sense and 
HOHYDWHV WKH GUDIWVPDQ·V DUW RYHU WKH ORQJ-­standing 
prohibition on patenting of products and laws of 
nature. 
Because it is not possible to study or use the 
genes unless they are isolated, the claims have 
significant implications.  The claims preempt any use 
of the genes for any purpose.  This has serious and 
urgent consequences for patients today, who often 
cannot obtain information about their own genes and 
thus cannot make educated medical decisions about 
breast and ovarian cancer surveillance and 
treatment.  Myriad has a monopoly on clinical 
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testing of its genes in the U.S., dictating the type and 
terms of BRCA genetic testing.  Myriad has given 
women false negative results, while also barring 
other laboratories from testing genes to verify the 
DFFXUDF\ RI0\ULDG·V UHVXOWV  $OWKRXJK0\ULDG KDV
not exercised its authority to stop all research, 
0\ULDG·VFODLPVKDYHKDGDSURYHQFKLOOLQJHffect on 
research, as laboratories are dissuaded from 
pursuing scientific work that requires using the 
patented genes. 
Even more disturbingly, because the claims 
reach all possible uses of the claimed genes, Myriad 
is authorized to block avenues of scientific inquiry.  
Myriad can prevent researchers from determining if 
mutations on the genes correlate with increased risk 
of other diseases.  It can prevent researchers from 
determining whether the genes could be used in 
therapy, and if they could, Myriad can prevent that 
use or lay claim to it.  Myriad can stop the 
development of new types of clinical testing of the 
genes that take advantage of recent scientific 
insights.  If it were determined that the genes could 
be used for purposes not now known, such as a 
substitute for silicon chips in computers (a use 
currently being explored by companies), Myriad can 
prevent that use.  Myriad can even prevent scientists 
from looking at their own genes. 
This case does not involve a challenge to the 
method for removing BRCA1 and BRCA2 from the 
body, nor the process of testing the genes for 
mutations, nor any drugs developed as a result of 
scientific research involving the genes.  The only 
question presented by this case is whether human 
genes can themselves be patented.  Because the 
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patents grant exclusive rights over natural 
phenomena and create barriers to scientific progress 
and medical care, they must be held invalid.    
STATEMENT OF THE CASE 
 7KH GLVWULFW FRXUW·V RSLQLRQ FRQWDLns an 
extensive discussion of the science of DNA and genes, 
which was supplemented by the Circuit opinions.  
Pet. App. 254a-­72a, 13a-­20a. 
a.  Nature of Human Genes and DNA 
Every human body contains genes that 
determine, in part, the structure and functions of the 
body.  Pet. App. 255a-­56a, 258a-­59a;; 1J.A. 130-­31, 
227-­28.  The structure and function of human genes 
are created by nature.  Pet. App. 259-­260a;; 1J.A. 58-­
59, 63, 91-­92, 130-­31, 133, 135, 224-­25, 232, 234-­35, 
264, 274-­75, 688-­89, 703-­04, 707.   
A gene is a segment of chromosomal DNA.  
Pet. App. 258a;; 1J.A. 229-­230.1  DNA is composed of 
four repeating elements called nucleotides or bases.  
Pet. App. 257a.  The nucleotides are products of 
nature.  1J.A. 132. 
A gene is defined based on its naturally-­
RFFXUULQJ TXDOLWLHV  ´(DFK JHQH LV W\SLFDOO\
WKRXVDQGV RI QXFOHRWLGHV ORQJ DQG XVXDOO\ ¶HQFRGHV·
one or more proteins, meaning it contains the 
information used by the body to produce those 
SURWHLQVµ  3Ht. App. 258a.  Nucleotides are 
represented by four letters, standing for each of the 
                                                 
1 Because genes are simply segments of DNA, references to 
DNA in this brief are, unless otherwise noted, references to a 
DNA segment that constitutes the BRCA1 or BRCA2 genes. 
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four nucleotides that make up DNA:  A (adenine), C 
(cytosine), T (thymine), and G (guanine).  Pet. App. 
257a.  The linear order of the nucleotides is referred 
to as the nucleotide sequence or gene sequence or 
DNA sequence.  Pet. App. 259a.  The gene sequence 
is a product of nature and its role in creating proteins 
(polypeptides) is a law of nature.  Pet. App. 260a.   
Genes are chemicals, but they are unique 
because they are much more;; they embody the 
information and instructions the body uses to 
function.  Pet. App. 259a-­60a, 355a-­56a;; 1J.A. 58-­59, 
130-­33, 135-­36, 232, 234-­35, 561-­62, 649-­50, 680-­81.  
They determine which polypeptides (proteins) will be 
made to do the work of the body.  Pet. App. 258a, 
266a-­67a;; 1J.A. 132-­33, 227-­  *HQHV ´GHILQH
physical traits such as skin tone, eye color, and sex, 
in addition to influencing the development of 
FRQGLWLRQV VXFK DV REHVLW\ GLDEHWHV $O]KHLPHU·V
disease and bipolar disorder.µ 3HW$SSD 7KH
genes themselves embody laws of nature and the 
processes by which genes do these things are laws of 
nature.  Pet. App. 257a-­62a, 334a-­37a;; 1J.A. 229-­30. 
Genes vary from one individual to another.  
Genetic variants can be inherited or can develop 
after birth, but the process by which the changes 
occur is a law of nature and the resultant variant 
gene is a product of nature.  Pet. App. 260a-­61a, 
270a, 378a;; 1J.A. 38-­45, 132-­33,135-­36, 224, 230-­31.  
Genetic variants can be as small as a single deletion 
(ATAG becomes ATG) or single substitution (ATAG 
becomes CTAG).  Pet. App. 260a-­61a.  They can also 
EHODUJHZLWKWKH´DGGLWLRQRUGHOHWLRQRIVXEVWDQWLDO
FKURPRVRPDO UHJLRQVµ  3HW $SS D  *HQHWLF
YDULDQWV FDQ DOVR ´LQYROY>H@ WKH GHOHtion or 
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GXSOLFDWLRQ RI XS WR PLOOLRQV RI QXFOHRWLGHVµ  3HW
App. 261a.  Variation in the human genome is very 
common.  Pet. App. 260a;; 1J.A. 230.  There is not one 
JHQHWKDWLV´QRUPDOµZLWKDIHZLQGLYLGXDOVKDYLQJ
variants;; much variation exists in the genes from one 
person to another.  1J.A. 230.  Myriad claims every 
version of the BRCA1 gene, but lists just one version 
LQ WKH SDWHQWV  3DWHQW · ),*  -$ -­45.  
The capital letters in FIG 10 represent the 
QXFOHRWLGHVFDOOHG´FRGLQJµDQGWKHOower case letters 
UHSUHVHQW QXFOHRWLGHV FDOOHG ´QRQ-­FRGLQJµ EHFDXVH
they are thought to be unnecessary in the creation of 
the protein. 
Variants can appear to be unimportant, 
correlate with an increased risk of disease or disorder 
´PXWDWLRQVµ RU KDYH XQknown significance 
´YDULDQW RIXQFHUWDLQ VLJQLILFDQFHµ 3HW$SS D
261a;; 1J.A. 231-­32.  The significance of the variant is 
created entirely by nature.  Pet. App. at 270a;; 1J.A. 
58-­59, 135-­36, 224, 231-­32.  
Some mutations in the BRCA1 or BRCA2 
genes correlate with an increased risk of breast 
and/or ovarian cancer.  Pet. App. 20a, 278a, 309-­
D3DWHQW ·-­-$ ´:RPHQZLWK
BRCA1 and BRCA2 mutations face up to an 85% 
cumulative risk of breast cancer as well as an up to 
50% cumulative risk of ovarian cancer. . . . The 
existence of BRCA1 or BRCA2 mutations is therefore 
an important consideration in the provision of 
FOLQLFDO FDUH IRU EUHDVW DQGRU RYDULDQ FDQFHUµ 3HW
App. 278a;; 1J.A. 205-­06.   As the district court found 
´PXWDWLRQV DOong with any association with a 




gene sequence, including its relationship to any 
GLVHDVHLVGLFWDWHGE\QDWXUHµ3HW$SSD 
b.  Scientific Uses of Genes 
It is useful for pathologists, clinical laboratory 
scientists, other medical professionals, and 
researchers to conduct genetic testing for clinically 
significant alterations.  Pet. App. 18a, 263a, 270a-­
72a, 378a, 380-­81a;; 1J.A. 58-­59, 132-­33, 209-­10, 232.  
Sequencing methods are used to examine the precise 
RUGHURI WKHJHQH·VQXFOHRWLGHV 3HW$SSD-­60a, 
263a, 270a-­72a;; 1J.A. 58-­59, 133-­35, 209-­10, 223, 
232-­35;; 2J.A. 854.  Thousands of medical 
professionals around the world sequence genes daily, 
and the processes by which sequencing is done are 
not at issue here.  Pet. App. 272a, 379a;; 1J.A. 58-­59, 
125-­26, 133-­136, 218, 223, 232, 234-­35.  At the end of 
the sequencing process, the medical professional has 
a long string of the four letters (A, C, T, and G) that 
correspond to the four nucleotides.  Pet. App. 257a, 
378a;; 1J.A. 58-­59, 131-­32, 230, 232.  The structure, 
function, and sequence of the nucleotides are created 
entirely by nature.  Pet. App. 260a, 343a;; 1J.A. 234-­
35, 644-­46, 653-­54, 676, 688-­89.  After sequencing, 
the medical professional looks to see if there are 
variants;; e.g., whether natural processes have caused 
there to be a C where a T would commonly be.  1J.A. 
58-­59, 135-­36, 232.  See, e.g., Pet. App. 426a (Patent 
·FOD. 
0\ULDG·V SDWHQW FODLPV KDYH SUHYHQWHG ODEV
other than Myriad from sequencing the BRCA1 and 
BRCA2 genes and looking to see if there are 
mutations, actions that are crucial to women and 
their families facing hereditary breast and ovarian 
cancer risk.  E.g., 1J.A. 60, 87-­89, 219-­220.  In many 
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cases, the effect has been devastating.  Some women 
have obtained testing from Myriad that gave them 
false negative results because Myriad did not include 
certain mutations in its standard testing.  Tom 
Walsh et al., Spectrum of Mutations in BRCA1, 
BRCA2, Chek2, and TP53 in Families at High Risk of 
Breast Cancer-$P0HG$VV·Q-­86 
(2006).  Women and their families make life-­
changing decisions based on testing provided by one 
company, without the option of seeking a second 
opinion.  See id.;; see also 1J.A. 76, 78-­79, 119.  
District court plaintiffs Ceriani and Fortune, both 
breast cancer patients, sought critical testing 
recommended by their doctors but were denied when 
Myriad would not accept their insurance.  1J.A. 121-­
22, 118-­119.  Plaintiffs Raker and Thomason needed 
PRUH H[WHQVLYH WHVWLQJ WKDQ RIIHUHG E\ 0\ULDG·V
standard test to screen for additional BRCA 
mutations but Myriad charged prohibitively for that 
testing.  1J.A. 75, 70-­71.  All of the plaintiff 
geneticists were willing to perform the tests for free 
or for an affordable cost but were prevented from 
doing so by 0\ULDG·V SDWHQW FODLPV E.g., 1J.A. 60, 
88-­89, 221-­22. 
But because the patent claims are not limited 
to the use of the genes in BRCA1 or BRCA2 testing, 
the effects have been far greater.  The patent claims 
have deterred research as other researchers, 
including plaintiffs Harry Ostrer, Wendy Chung, and 
David Ledbetter, are chilled from engaging in 
scientific work using these genes.  1J.A. 144-­48, 220, 
714-­18.  Plaintiff Runi Limary was told by Myriad 
WKDW VKHKDVD ´YDULDQW RIXQFHUWDLQ VLJQLILFDQFHµ D
result that only Myriad can further explain given 
WKHLU FRQWURO RYHU SDWLHQWV· %5&$ JHQHWLF
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information.  1J.A. 81-­83;; see also 1J.A. 61-­62, 91, 
113-­14, 206-­09, 222-­23.  And the research that has 
been deterred or prevented is not limited to research 
into breast and ovarian cancer, but to any research 
on these genes and their effects. 
It is not currently possible to use genes, 
including looking at or sequencing them, without 
UHPRYLQJ RU ´LVRODWLQJµ WKHP IURP WKH ERG\  3HW
App. 271a, 342a.  The isolated gene, however, is not 
´PDUNHGO\ GLIIHUHQWµ LQ HLWKHU VWUXFWXUH RU IXQFWLRQ
from a gene in the body.  Most importantly, the 
nucleotides that make up DNA ² RU '1$·V
´LQIRUPDWLRQFRQWHQWµ² remain the same.  Pet. App. 
D ,IWKDWZHUHQRWWKHFDVH0\ULDG·VGLDJnostic 
use of the gene would be futile.  After isolating and 
sequencing the gene utilizing conventional methods, 
Myriad reports to the person who provided the 
sample that the gene in the body does or does not 
have a harmful mutation because the isolated gene 
does or does not have that mutation. Pet. App. 278a-­
D  ,I WKH ´LVRODWHGµ JHQH LQ WKH ODE GLIIHUHG IURP
the gene in the body, Myriad could not reach that 
conclusion.  Pet. App. 224a.  And classic experiments 
established that when isolated DNA is reinserted 
into the cell, it functions as it did previously.  1J.A. 
650-­53.   
Isolation does separate the gene from other 
parts of the body to which it is normally attached.  
The gene in the body is normally surrounded by and 
sometimes attached to other things, including 
proteins, that are collectively called chromatin.  Pet. 
App. 262a;; 1J.A. 644-­46, 685-­86.  But the gene 
sequence, the information it includes, and the laws it 
embodies are the same whether in or out of the body.  
10 
 
Pet. App. 262a, 336a;; 1J.A. 644-­46.  Even if 
separation from the chromatin were considered to 
create a structural difference, DNA is separated from 
the chromatin in the body during several naturally-­
occurring processes;; the gene separated from the 
chromatin can be found in the body.  Pet. App. 264a.  
Isolation also separates the chromosome into 
fragments, breaking the bonds that link the pieces of 
the chromosome itself.  Once again, the gene 
sequence, the information it includes, and the laws it 
embodies are the same whether the gene is in the 
body or contained in fragments made during the 
isolation process.  But even if cutting the 
chromosome into pieces were considered to constitute 
a structural change, gene fragments exist in the 
body.  These fragments result from naturally-­
occurring processes that break the bonds that hold 
the full chromosome together.2  Those fragments are 
                                                 
2 Nature breaks the bonds that hold together the full 
chromosome (1) every time gametes are produced during the 
normal process of meiotic recombination;; (2) during the cellular 
process by which cells make copies of themselves;; (3) when DNA 
experiences a double strand break (which then is often 
repaired).  See Wolf-­Dietrich Heyer et al., Holliday Junctions in 
the Eukaryotic Nucleus: Resolution in Sight?, 28 Trends in 
Biochemical Sci. 548 (2003);; see also Robyn L. Maher et al., 
Coordination of DNA Replication and Recombination Activities 
in the Maintenance of Genomic Stability, 112 J. of Cellular 
Biochemistry 2672 (2011). 
The entire fetal and maternal genome can also be found in 
short fragments with broken covalent bonds in maternal 
plasma, and DNA can also be found in the blood of those 
suffering from cancer.  Y.M. Dennis Lo et al., Maternal Plasma 
DNA Sequencing Reveals the Genome-­Wide Genetic and 
Mutational Profile of the Fetus, 2 Sci. Translational Med. 
61ra91 at 1 (2010);; Maurice Stroun et al., Isolation and 
11 
 
identical to the fragments created by Myriad when it 
isolates the gene.3  
c.  The Patents 
 Petitioners challenge nine patent claims on 
human genes.  None of the challenged claims is 
limited to any particular use of the genes, any form 
of recombinant DNA, or a therapy (including a drug) 
involving the genes.  None is limited to a method of 
looking at the gene.  All of the claims are to the genes 
themselves and reach all structures and uses of the 
gene. 
 7KHNH\FODLPVDUHFODLPRI3DWHQW·DQG
FODLP  RI 3DWHQW ·  7KRVH FODLPV UHDFK DQ\
´LVRODWHG '1$µ WKDW ZLOO FUHDWH WKH SURWHLQV
                                                                                                    
Characterization of DNA from the Plasma of Cancer Patients, 23 
Eur. J. Cancer & Clinical Oncology 707 (1987). 
3 In the process of isolating a gene, DNA is fragmented and 
covalent bonds are broken.  The scientist, however, does not 
decide or control the size or composition of the fragments;; they 
are of random length and composition. Indeed, if a scientist 
were to isolate a gene of a person on Monday, and then do so 
again on Tuesday, it is likely the fragments would have a 
different size and composition.  Many fragments are likely to 
include a portion of the BRCA1 or BRCA2 gene and a portion of 
the adjacent DNA.  Bruce Alberts et al., Molecular Biology of 
the Cell Ch. 8 (4th ed. 2002);; Robert L. Nussbaum et al., 
Thompson and Thompson Genetics in Medicine Ch. 4 (7th ed. 
2007);; Harvey Lodish et al., Molecular Cell Biology Ch. 7-­8 (4th 
ed. 2000).  
In addition, scientists sequencing genes after isolation 
generally do not chemically stitch the fragments back together 
to form longer segments, such as an entire gene.  See 1J.A. 690-­
91.  Sequencing generally relies on computers to recreate the 
gene sequence without creating a molecule or chemical that is 
an entire gene.  Id.  
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naturally created by the BRCA1 and BRCA2 genes.  
0RUH VSHFLILFDOO\ 3DWHQW · FODLP  UHDFKHV WKH
BRCA1 gene:   
An isolated DNA coding for a BRCA1 
polypeptide, said polypeptide having the 
amino acid sequence set forth in SEQ 
ID No. 2. 
Pet. App. 426a.  SEQ ID No. 2 refers to a lengthy 
sequence of amino acids set forth in the patent.  
3DWHQW · FODLP  LV YLUWXDOO\ LGHQWLFDO UHDFKLQJ
the BRCA2 gene.   
An isolated DNA molecule coding for a 
BRCA2 polypeptide, said DNA molecule 
comprising a nucleic acid sequence 
encoding the amino acid sequence set 
forth in SEQ. ID. No. 2. 
Pet. App. 427a. 
All of the remaining claims use alternate 
terms to define the same genes or duplicatively claim 
alternate forms of the genes. 
 All nine claims use the same definitions of the 
WZRNH\ WHUPV  ´LVRODWHGµ DQG ´'1$µ  ´,VRODWHGµ LV
GHILQHG DV  ´$Q ¶LVRODWHG· « QXFOHLF DFLG e.g. an 
RNA, DNA, or a mixed polymer) is one which is 
substantially separated from other cellular 
components which naturally accompany a native 
KXPDQVHTXHQFHRUSURWHLQµ3DWHQW·-­12, 
2J$    7KLV GHILQLWLRQ RI ´LVRODWHGµ FRPSRUWV
with the ordinary understanding of the term in the 
field and there is no dispute between the parties over 
the meaning of the term. 
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´'1$µ LV GHILQHG EURDGO\  7KH FODLPV UHDFK
´DOOIRUPVRIPXWDWLRQVµ3DWHQW·-­32, 2J.A. 
 DQG ´DOO DOOHOLF >QXFOHRWLGH@ YDULDWLRQVµ 3DWHQW
·-­40, 2J.A. 755).  They reach any DNA if it 
is as little as 60% similar to the specified DNA 
3DWHQW ·  -$  DQG DQ\ '1$ WKDW
creates proteins as little as 30% similar to the 
VSHFLILHGSURWHLQV 3DWHQW ·-­63, 2J.A. 757).  
They reach all fragments of both the DNA and the 
proteins.  See 3DWHQW · -­28, 2J.A. 748 
´FRPSULVLQJDOORUDSRUWLRQRIWKH%5&$ORFXVRURI
a mutated BRCA1 locus, pUHIHUDEO\DWOHDVWEDVHVµ
3DWHQW·-­-$UHDFKHV'1$WKDW´FDQ
«SURGXFH«WKHSRO\SHSWLGHRUDIUDJPHQWWKHUHRIµ
3DWHQW · -­43, 2J.A. 755 (reaches DNA that 
SURGXFHV ´IUDJPHQW KRPRORJ RU YDULDQWµ RI
SURWHLQV3DWHQW·20:34-­35, 2J.A.755 (fragments 
DV VKRUW DV  QXFOHRWLGHV 3DWHQW · -­65, 
2J.A. 755 (fragments as short as 8 nucleotides);; 
3DWHQW ·-­35, 2J.A. 758 (fragments as short 
as 5 amino acids).  In 1998, Myriad wrote to one of 
the plaintiffs, Dr. Kazazian, and said specifically that 
WKH SDWHQWV FRYHUHG ´DQ\ IUDJPHQWV RI WKH %5&$
JHQHµ-$-­69. 
The claims also reach other forms of genetic 
PDWHULDO7KH\LQFOXGH´51$F'1$JHQRPLF'1$
V\QWKHWLF IRUPV    µ  3DWHQW · -­53, 2J.A. 
755.4  7KH\ UHDFK'1$ZLWK RUZLWKRXW ´DOO FRGLQJ
sequences, all intervening sequences and regulatory 
HOHPHQWVµ  3DWHQW · -­40, 2J.A. 755.  They 
                                                 
4 cDNA, or complementary DNA, is discussed in Section II, 
infra.  In short, it is DNA without the non-­coding regions 




UHDFK '1$ PRGLILHG E\ ´PHWK\ODWLRQµ RU RWKHU
naturally-­occurring biochemical or chemical 
modifications RUQRWVRPRGLILHG3DWHQW·-­
55, 2J.A. 755;; see also Pet. App. 263a. 
7KH NH\ FODLPV 3DWHQW · FODLP  DQG
3DWHQW·FODLPGHILQHWKHJHQHVE\WKHIXQFWLRQ
given to the genes by nature and are not limited to 
any particular molecular structure or any particular 
use.  Pet. App. 426a-­27a.  Because nature dictates 
that numerous DNA sequences can result in those 
polypeptides (proteins), 1J.A. 685-­86, these claims 
unquestionably reach all uses of multiple 
compositions created by nature and defined by laws 
of nature, whether or not Myriad or anyone else has 
identified those compositions. 
&ODLPRI3DWHQW ·GHILQHVWKHH[DFWVDPH
gene by referring to a sequence of nucleotides that in 
nature represents one version of the BRCA1 gene.  It 
reads:   
The isolated DNA of claim 1, wherein 
said DNA has the nucleotide sequence 
set forth in SEQ ID No. 1. 
Pet. App. 426a.  This sequence reference is to a 
nucleotide sequence listed in the patent.  Because the 
SDWHQWV GHILQH WKH WHUP ´'1$µ XVHG LQ WKLV FODLm 
identically to claim 1 to include all versions of the 
nucleotide sequence (and more), the sequence 
referenced is solely illustrative. 
 Indeed, if the claim reached only the specific 
sequence identified in the table, it would be 
confounding to geneticists who would not know if 
they infringed (i.e., found that identical sequence) 
until they infringed (sequenced the gene).  The claim 
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would also be useless to Myriad.  It is unlikely that 
more than a few people possess that exact sequence.  
If the specified sequence were the only sequence 
covered, it would not reach any sequence with any 
variants, mutations, or alterations.  There is nothing 
in the patents to suggest that variants including non-­
coding regions are excluded from the definition of 
DNA.   
The remaining claims are alternate 
descriptions, duplicative of the key claims, though 
three are of extraordinary breadth.  Claim 6 of 
3DWHQW·UHDFKHVDQ\LVRODWHG%5&$'1$ZLWKD
PXWDWLRQ WKDW LV ´DVVRFLDWHGZLWKD VXVFHSWLELOLW\ WR
FDQFHUµ,WUHDGV 
An isolated DNA molecule coding for a 
mutated form of the BRCA2 polypeptide 
set forth in SEQ ID No. 2, wherein said 
mutated form of the BRCA2 polypeptide 
is associated with a susceptibility to 
cancer. 
Pet. App. 427a.  The claim reaches any BRCA2 gene 
with harmful mutations regardless of whether 
another geneticist is the one who finds the mutation 
and identifies it as associated with any type of 
cancer.  Indeed, for another geneticist to look for and 
find such a mutation would be infringing. 
Claims 5 and 6 of pateQW · UHDFK DQ\
segment of the BRCA1 DNA as short as 15 
nucleotides.  Claim 5 reaches any segment as short 
as 15 nucleotides that will create the proteins or any 
portion of the protein.  Pet. App. 426a.  Claim 6 
reaches any 15 nucleotides of the BRCA1 gene.  Id.  
More specifically, the claims read: 
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5.  An isolated DNA having at least 15 
nucleotides of the DNA of claim 1. 
6.  An isolated DNA having at least 15 
nucleotides of the DNA of claim 2. 
%HFDXVH WKH FODLPV UHDFK'1$KDYLQJ ´DW OHDVWµ 
nucleotides, they reach longer sequences as well, 
including the entire gene.  They also reach other 
genes.  Because DNA is composed solely of the four 
nucleotides, there is extensive repetition in the 
genome.  And, because the BRCA1 gene is large, it 
includes a huge number of 15 nucleotide sequences.  
Fifteen (15) nucleotide sequences from the BRCA1 
gene can be found in virtually every other gene in the 
body.  1J.A. 631-­34, 662-­72.  Moreover, as Judge 
Bryson indicated, claim 6 reaches nucleotide 
sequences in the non-­coding regions as well as the 
coding regions throughout the genome.  Pet. App. 
114a. 
7KHRWKHUFODLPVFODLPRISDWHQW·FODLP
 RI SDWHQW · DQG FODLP  RI SDWHQW · UHDFK
more specific, identified mutations.  Pet. App. 426a, 
428a.  For example, FODLPRI·UHDGV 
An isolated DNA selected from the 
group consisting of: (a) a DNA having 
the nucleotide sequence set forth in 
SEQ ID No. 1 having T at nucleotide 
position 4056 . . . 
These claims represent nothing more than Myriad 
describing a gene that contains some of the 
mutations caused by nature that nature has caused 
to be significant.  Any geneticist must infringe 
(isolate the gene with the mutation) before she can 
determine that she has infringed (look to see if the 
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composition includes the specified mutation).  As 
with all the claims, they are not limited to any 
particular use.  
d.  Proceedings Below 
This lawsuit began in 2009 with the filing of a 
complaint in the United States District Court for the 
Southern District of New York against the PTO, as 
well as the patent holders, Myriad Genetics and the 
directors of the University of Utah Research 
Foundation.5  Plaintiffs included four national 
organizations of physicians, geneticists, researchers, 
clinicians, and other health professionals with a 
combined total of over 150,000 members, as well as 
VL[ RI WKH QDWLRQ·V OHDGLQJ JHQHWLFLVWV WZR JHQHWLF
FRXQVHORUV WZR ZRPHQ·V KHDOWK DQG EUHDVW FDQFHU
organizations, and six individual women who have 
been diagnosed with or are at risk of hereditary 
breast or ovarian cancer.  Pet. App. 240a-­48a. 
Plaintiffs alleged in their complaint that the 
patent claims are invalid under Section 101 of the 
Patent Act because they cover products and laws of 
nature and abstract ideas.  They also alleged that the 
effect of the challenged patent claims is to preempt 
scientific inquiry and medical care to the detriment 
RI SDWLHQWV· KHDOWK DQG VFLHQWLILF DGYDQFHPHQW LQ
violation of the First Amendment and Article I of the 
U.S. Constitution.  
 The complaint challenged fifteen claims from 
seven different patents.  Pet. App. 297a-­303a.  Nine 
                                                 
5 The University of Utah Research Foundation is an owner or 
co-­owner of each of the patents containing the challenged 
claims, Pet. App. 248a, and has acted jointly with Myriad 
throughout the litigation.   
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of the challenged claims from three patents cover the 
BRCA1 or BRCA2 genes.6 
 Defendants moved to dismiss in the district 
court largely on the grounds that plaintiffs lacked 
standing.  Pet. App. 361a.  The court denied that 
motion.  Pet. App. 412a.  Both plaintiffs and Myriad 
subsequently moved for summary judgment, and the 
PTO moved for judgment on the pleadings.  Pet. App. 
D7KHGLVWULFWFRXUWJUDQWHGSODLQWLIIV·PRWLRQIRU
VXPPDU\MXGJPHQWDQGGHQLHG0\ULDG·VPRWLRQId.  
The constitutional claims against the PTO were 
dismissed based on the doctrine of constitutional 
avoidance.  Id. at 357a. 
 7KH GLVWULFW FRXUW·V -­page, comprehensive 
opinion, Pet. App. 232a-­357a, began by discussing 
the standard set by this Court for determining if a 
patented composition of matter ² OLNH WKH ´LVRODWHGµ
DNA at issue here ² has been sufficiently changed so 
that it is no longer a law or product of nature.  Pet. 
App. 320a-­23a (citing Diamond v. Chakrabarty, 447 
U.S. 303 (1980);; Funk Bros. Seed Co. v. Kalo 
Inoculant Co., 333 U.S. 127 (1948);; and American 
Fruit Growers, Inc. v. Brogdex Co., 283 U.S. 1 
(1931)).   
7KH GLVWULFW FRXUW FRQVLGHUHG 0\ULDG·V
arguments regarding both structural and functional 
GLIIHUHQFHV EHWZHHQ ´LVRODWHGµ '1$ DQG WKH '1$
inside the human body, ultimately concluding that 
QRQH FDXVHG ´LVRODWHGµ JHQHV WR EH ´PDUNHGO\
GLIIHUHQWµChakrabarty, 447 U.S. at 310, from genes 
in the body.  Pet. App. 333a-­44a.  In holding that 
                                                 
6 The complaint also challenged some method claims, none of 
which is now before the Court. 
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patents on isolated DNA claim laws and products of 
nature, the district court emphasized that the 
functionality of genes is based on their unique status 
as the embodiment of the information the body uses.   
[T]he information encoded by DNA 
reflects its primary biological function: 
directing the synthesis of other 
molecules in the body ² namely, 
SURWHLQV ´ELRORJLFDO PROHFXOHV RI
HQRUPRXV LPSRUWDQFHµ ZKLFK ´FDWDO\]H
ELRFKHPLFDO UHDFWLRQVµ DQG constitute 
WKH ´PDMRU VWUXFWXUDO PDWHULDOV RI WKH
DQLPDOERG\µ 
Pet. App. 335a.  The district court found that in 
LVRODWLQJ D JHQH0\ULDG GLG QRW ´DOWHU LWV HVVHQWLDO
characteristic ² its nucleotide sequence that is 
defined by nature and central to both its biological 
function within the cell and its utility as a research 
WRRO LQWKH ODEµ 3HW$SSD 7R WKHH[WHQWDQ\
claims reached cDNA, the court also invalidated 
those claims for largely the same reason.  Pet. App. 
339a.   
 Myriad appealed to the Federal Circuit.  
Plaintiffs did not appeal the dismissal of the PTO, 
although plaintiffs continued to raise their First 
Amendment claims against the University of Utah 
defendants.  The United States did, however, 
participate in the proceedings on the initial appeal 
and remand as amicus curiae, largely supporting 
plaintiffs.    
 A divided panel of the Federal Circuit 
reversed.  The panel first dismissed all but one of the 
plaintiffs on the grounds that unless they had been 
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personally threatened by Myriad, they did not have 
standing.  Pet. App. 32a-­42a.  Each panel member 
wrote a separate opinion discussing the patentability 
of human genes.  Judge Lourie held that in analyzing 
ZKHWKHU DQ ´LVRODWHGµ JHQH KDV ´PDUNHGO\ GLIIHUHQW
charaFWHULVWLFVµ IURP ZKDW LV IRXQG LQ QDWXUH WKH
functionality of the gene is irrelevant.  Pet. App. 55a.  
+HKHOGWKDW´LVRODWHGµ'1$LVVWUXFWXUDOO\GLIIHUHQW
from DNA on the sole basis that in the process of 
removing DNA from the rest of the chromosome to 
which it is attached, a covalent bond is broken.  Pet. 
App. 51a-­57a.  
Judge Moore, by contrast, found that both 
structure and function were relevant in determining 
LIDFRPSRVLWLRQLV´PDUNHGO\GLIIHUHQWµIURPZKDWLV
found in nature.  Pet. App. 85a.  She found that a 
full-­OHQJWK ´LVRODWHGµ JHQH ´GRHV QRW FOHDUO\ KDYH D
new utility and appears to simply serve the same 
HQGV GHYLVHG E\ QDWXUHµ  3HW $SS D-­86a.  She 
ZURWH  ´,I , ZHUH GHFLGLQJ WKLV FDVH RQ D EODQN
canvas, I might conclude that an isolated DNA 
sequence that includes most or all of a gene is not 
SDWHQWDEOH VXEMHFW PDWWHUµ  3HW $SS D  6KH
nevertheless found full-­length genes to be patentable 
EHFDXVH RI WKH 372·V SUDFWLFH RI JUDQWLQJ JHQH
patents and industry reliance on that practice.  Id.  
She also opined that small fragments of the gene 
would be patentable because they could be used as 
probes or primers, while recognizing that none of the 
patents claims is limited to small fragments.7  See 
Pet. App. 82a. 
                                                 
7 Probes and primers are pieces of DNA that are used in 
laboratories as part of the process of identifying or making 
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In his dissenting opinion, Judge Bryson held 
that the genes were not patentable.  Pet. App. 102a.  
He reasoned: 
The structural differences between the 
FODLPHG ´LVRODWHGµ JHQHV DQG WKH
corresponding portion of the native 
genes are irrelevant to the claim 
limitations, to the functioning of the 
genes, and to their utility in their 
isolated form.  The use to which the 
genetic material can be put, i.e., 
determining its sequence in a clinical 
setting is not a new use;; it is only a 
consequence of possession. In order to 
sequence an isolated gene, each gene 
must function in the same manner in 
the laboratory as it does in the human 
body. 
Pet. App. 110a.   
 Plaintiffs sought reconsideration by the panel 
on the grounds that the majority had introduced 
facts not in the record and that those facts were 
wrong.  Specifically, plaintiffs noted that fragments 
of DNA with broken covalent bonds are created both 
LQWKHERG\DQG LQWKH´LVRODWLRQµSURFHVV WKHUHIRUH
the breaking of a covalent bond did not distinguish 
´LVRODWHGµ '1$ IURP '1$ LQ WKH ERG\  3OV-­
$SSHOOHHV·3HWIRU3DQHO5HK·J$VV·QIRU0ROHFXODU
Pathology v. U.S. Patent & Trademark Office, 653 
                                                                                                    
copies of DNA.  Pet. App. 264a-­65a, 340a-­41a.  None of the 




F.3d 1329 (Fed. Cir. 2011);; see 1J.A. 688-­89.  
Rehearing was denied without opinion.8 
 7KLV &RXUW JUDQWHG SODLQWLIIV· SHWLWLRQ IRU
certiorari, vacated and remanded for further 
proceedings in light of Mayo Collaborative Services v. 
Prometheus Laboratories, Inc., 132 S. Ct. 1289 
(2012).  Upon remand, each panel member adhered 
to his or her previous views. 
 -XGJH /RXULH·V FRQVLGHUDWLRQ RI Mayo was 
limited to two short paragraphs, which purported to 
distinguish Mayo on the ground that its reference to 
the preemptive effect of the invalidated patent in 
WKDWFDVHZDVDSSOLFDEOHRQO\WR´ODZVRIQDWXUHµQRW
´SURGXFWV RI QDWXUHµ  5HMHFWLQJ WKH ILQGLQJV RI WKH
district court that DNA is a unique composition in its 
embodiment of natural laws, Judge Lourie ruled that 
the patents in this case do not claim a law of nature.  
Pet. App. 56a. 
Judge Moore, unlike Judge Lourie, thought 
that Mayo ´FOHDUO\ RXJKW WR DSSO\ HTXDOO\ WR
PDQLIHVWDWLRQVRIQDWXUHFRPSRVLWLRQFODLPVµ 3HW
App. 79a.  Even so, she did not alter her conclusion 
or analysis in any material way to reflect Mayo·V
holdings.  Neither she nor Judge Lourie even 
UHIHUUHG WR WKLV &RXUW·V DSSDUHQW UHMHFWLRQ RI KHU
´UHOLDQFHµDUJXPHQWLQMayo.  132 S. Ct. at 1305. 
 -XGJH%U\VRQ·VGLVVHQWLQJRSLQLRQDSSOLHGWKLV
&RXUW·VUHDVRQLQJLQMayo´+DVWKHDSSOLFDQWPDGH
                                                 
8 Myriad also filed a petition for panel rehearing, arguing that 
plaintiff Harry Ostrer lacked standing.  The petition was denied 
without opinion.  1J.A. 19.  Myriad raised the standing issue 
again following the Mayo remand, and the Federal Circuit 
rejected the argument in its second opinion.  Pet. App. 25a n.6. 
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DQ ¶LQYHQWLYH· FRQWULEXWLRQ WR WKHSURGXFW RIQDWXUH"
'RHV WKHFODLPHG LQYHQWLRQ LQYROYHPRUH WKDQ ¶ZHOO-­
XQGHUVWRRG URXWLQH FRQYHQWLRQDO· HOHPHQWV  +HUH
the answer to those questionVLVQRµ3HW$SSD
+H DOVR UHMHFWHG WKH PDMRULW\·V GHIHUHQFH WR SULRU
372 SUDFWLFH QRWLQJ WKDW LW ´JLYH>V@ WKH 372
lawmaking authority that Congress has not accorded 
LWµ3HW$SSD 
All three judges held that cDNA was 
patentable subject matter, e.g., Pet. App. 47a-­48a, 
80a-­D D LJQRULQJ WKH GLVWULFW FRXUW·V ILQGLQJV
that none of the claims is limited to cDNA, that 
cDNA results from natural phenomena, and that 
cDNA sequences are found in the human genome.  
Pet. App. 268a, 339a.  None of the Circuit judges 
addressed the claim to DNA with cancer-­associated 
mutations or the other four claims that reach other 
mutations.  None of the Circuit judges addressed 
3HWLWLRQHUV·FRQVWLWXWLRQDOFODLPV 
Petitioners again sought review by this Court 
and the petition was granted, limited to Question 1:  
´$UHKXPDQJHQHVSDWHQWDEOH"µ 
SUMMARY OF ARGUMENT 
0\ULDG·V SDWHQWV RQ %5&$ DQG %5&$
violate long-­established precedent that prohibits the 
patenting of laws and products of nature.  
Chakrabarty 86DW 7KH&RXUW·V VHPLQDO
Section 101 cases describe three different ways to 
evaluate patents to determine whether they 
impermissibly claim natural phenomena:  whether 
the patented composition has markedly different 
characteristics from any found in nature, id. at 310;; 
whether the patent is based on an inventive concept, 
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Mayo, 132 S. Ct. at 1294;; and whether the patent 
preempts use of the underlying product or law of 
nature, foreclosing future innovation out of 
SURSRUWLRQ ZLWK WKH SDWHQWHH·V FRQWULEXWLRQ id. at 
1301-­03.  When these three standards are applied to 
0\ULDG·V FODLPV LW LV FOHDU WKDW WKH SDWHQWV Rn 
isolated DNA must be found invalid.   
First, isolated DNA does not have markedly 
different characteristics from any found in nature.  
Isolated DNA is simply removed from its natural 
environment;; its structure and function remain the 
same.  It also embodies the same genetic information 
² a law of nature ² as in the body.  The difference in 
structure discussed by the Federal Circuit majority 
opinion is based on a scientific misunderstanding, 
but even if correct, isolated DNA still could not be 
FRQVLGHUHG´PDUNHGO\GLIIHUHQWµIURPWKH'1$LQWKH
body. 
Second, patents on isolated DNA are not based 
on any inventive concept.  Isolation was a routine, 
conventional activity at the time these patents were 
obtained.  The only addition to the progress of science 
disclosed by these claims is the law of nature itself:  
that this DNA encodes for the BRCA1 or BRCA2 
gene or protein.  As in Funk Brothers 0\ULDG·V
GLVFRYHU\ LV VLPSO\ RI QDWXUH·V KDQGLwork.  See 333 
U.S. at 131. 
Third, patenting isolated DNA ties up all basic 
uses of the BRCA1 and BRCA2 genes, foreclosing 
more future innovation than the underlying 
discovery could reasonably justify.  See Mayo, 132 S. 
Ct. at 1301.  Because isolation is required for any 
serious study, examination, or clinical or commercial 
use of the genes, these patents preempt all such 
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activity.  The patents exclude using the genes for 
research, clinical genetic testing, and the 
development of therapies.  And these fears are not 
hypothetical;; in practice, Myriad has used its patents 
to shut down clinical care and impede research. 
The Court need not reach the question of 
whether cDNA, or complementary DNA, is 
patentable.  Myriad has never argued that any of its 
claims are limited to cDNA, nor could it given the 
definitions in the patents.  Even if some claims were 
VR OLPLWHG F'1$·V VWUXFWXUH LV GLFWDWHG E\ QDWXUH
and created by natural processes.  Its function is 
likewise dictated by nature.  It is neither inventive 
nor markedly different from DNA, and patenting it 
preempts use of a basic scientific and technological 
tool. 
Patent-­eligibility cannot be satisfied by the 
372·VSROLF\RILVVXLQJSDWHQWVRQLVRODWHG'1$DQG
the industry reliance on such patents.  This Court 
has QHYHU GHIHUUHG WR WKH 372·V 6HFWLRQ 
determinations, especially where, as here, they 
YLRODWH WKLV &RXUW·V RZQ SUHFHGHQW  0RUHRYHU LQ
Mayo, the Court rejected the same arguments about 
industry reliance made by Prometheus and Myriad, 
as amicus. 
Finally, these patents run afoul of the First 
Amendment because they lock up the body of 
knowledge about these two genes.  Myriad (and 
specifically in this context, the University of Utah) 
has the right to exclude all others from examining 
these genes in any context.  Such restrictions on an 
entire field of knowledge give control over thought 
and pure information, in violation of the 




I.   ´,62/$7(' '1$µ ,6 12T PATENTABLE 
SUBJECT MATTER UNDER SECTION 
101. 
The patenting of isolated DNA violates long-­
established precedent that prohibits the patenting of 
laws of nature, natural phenomena, products of 
nature, and abstract ideas.  Chakrabarty, 447 U.S. at 
309;; see also J.E.M. Ag Supply, Inc. v. Pioneer Hi-­
%UHG ,QW·O ,QF, 534 U.S. 124, 134 (2001) ´¶WKH
UHOHYDQW GLVWLQFWLRQ· IRU SXUSRVHV RI   LV   
¶EHWZHHQ SURGXFWV RI QDWXUH ZKHWKHU Oiving or not, 
and human-­PDGH LQYHQWLRQV·µ  ´>7@KHVH H[FHSWLRQV
have defined the reach of the statute as a matter of 
statutory stare decisis JRLQJEDFN\HDUVµBilski 
v. Kappos, 130 S. Ct. 3218, 3225 (2010) (citing Le Roy 
v. Tatham, 55 U.S. 156, 174-­´3KHQRPHQD
of nature, though just discovered, mental processes, 
and abstract intellectual concepts are not patentable, 
as they are the basic tools of scientific and 
WHFKQRORJLFDO ZRUNµ  Mayo, 132 S. Ct. at 1293 
(quoting Gottschalk v. Benson, 409 U.S. 63, 67 
(1972)).  This Court has explained repeatedly that 
´>V@XFKGLVFRYHULHVDUH¶PDQLIHVWDWLRQVRIQDWXUH
IUHH WR DOO PHQ DQG UHVHUYHG H[FOXVLYHO\ WR QRQH·µ
Chakrabarty, 447 U.S. at 309 (quoting Funk Bros., 
86DW2WKHUZLVH´WKHUHLVDGDQJHUWKDW
the grant of patents that tie up their use will inhibit 
IXWXUH LQQRYDWLRQSUHPLVHGXSRQ WKHPµ Mayo, 132 
S. Ct. at 1301;; see also Funk Bros., 333 U.S. at 130-­
31. 




fundamental understanding that they are not the 
NLQG RI ¶GLVFRYHULHV· WKH VWDWXWH ZDV HQDFWHG WR
SURWHFWµ Parker v. Flook, 437 U.S. 584, 593 (1978).  
A product of nature does not become a patentable 
invention based on utility, novelty, hard work, or the 
need to recoup investment.  See Mayo, 132 S. Ct. at 
1304.  Nor can clever draftsmanship ² such as adding 
WKHZRUG ´LVRODWHGµ ² rescue a claim that otherwise 
IDOOV VKRUW RI 6HFWLRQ  VFUXWLQ\  7KH &RXUW·V
´FDVHVZDUQ XV DJDLQVW LQWHUSUHWLQJ SDWHQW VWDWXWHV
LQZD\V WKDWPDNH SDWHQW HOLJLELOLW\ ¶GHSHQG VLPSO\
RQ WKH GUDIWVPDQ·V DUW· ZLWKRXW UHIHUHQFH WR Whe 
¶SULQFLSOHVXQGHUO\LQJWKHSURKLELWLRQDJDLQVWSDWHQWV
IRU >QDWXUDO ODZV@·µ  Id. at 1294 (quoting Flook, 437 
U.S. at 593).   
The central question in this case is whether 
´LVRODWHG'1$µLVDQXQSDWHQWDEOHSURGXFWRUODZRI
nature or a patentable invention.  In Mayo, 
Chakrabarty, Funk Brothers, and American Fruit 
Growers, this Court has identified at least three 
different ways of distinguishing a product or law of 
nature from a patentable invention:  whether the 
composition has any markedly different 
characteristics from any found in nature;; whether 
the patent is based on an inventive concept;; and 
whether the patent ties up use of the underlying 
natural phenomena. The three ways do not appear to 
be independent tests but ways of approaching the 
central question that must be applied on a case-­by-­
case basis.  When each is applied to the patent claims 
challenged in this case, the claims must be held 
invalid.  Isolated DNA does not have markedly 
different characteristics from any found in nature, it 
is not based on an inventive concept, and patenting it 
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preempts a huge number of valuable applications, far 
more than the underlying discovery can justify.   
A.  Isolated DNA Does Not Have 
Markedly Different Characteristics 
From Any Found In Nature. 
In Diamond v. Chakrabarty, the last case in 
which this Court considered whether a composition 
of matter was patentable subject matter under 
Section 101, the Court held that a patent-­eligible 
FRPSRVLWLRQPXVWKDYH´DGLVWLQFWLYHQDPHFKDUDFWHU
>DQG@ XVHµ DQG ´PDUNHGO\ GLIIHUHQW FKDUDFWHULVWLFV
IURPDQ\IRXQGLQQDWXUHµChakrabarty, 447 U.S. at 
309-­10 (alteration in original) (citation omitted).  
7KHVH FULWHULD DUH FRQVLVWHQW ZLWK WKH &RXUW·V
statements in earlier Section 101 cases, including 
Funk Brothers and American Fruit Growers, and 
should guide the patent-­eligibility determination 
here.  Isolated DNA does not meet this standard. 
Chakrabarty involved patents on bacteria that 
had been genetically-­engineered to contain two or 
more plasmids, each capable of breaking down a 
component of crude oil, thus allowing the bacteria to 
degrade oil.  Id. at 305.  In concluding that the 
Chakrabarty bacterium was not a product of nature, 
the Court did not simply ask whether the bacterium 
was naturally-­occurring, as had the Patent Office 
Board of Appeals below.  Id. at 306 n.3.  Instead, the 
Court delved deeper, examining the key 
characteristics of the claimed composition, including 
structure and function, to determine whether it was 
the work of nature.   
Comparing the unpatentable combination of 
bacteria in Funk Brothers with the genetically-­
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engineered and patentable Chakrabarty bacterium, 
the Court in Chakrabarty concluded that the latter 
KDV ´PDUNHGO\ GLIIHUHQW FKDUDFWHULVWLFV IURP DQ\
IRXQG LQ QDWXUHµ ZKLOH WKH IRUPHU·V GLVFRYHU\ LV
´QDWXUH·VKDQGLZRUNµ Id. at 310.  The Chakrabarty 
bacterium was both structurally and functionally 
different from the bacterium in its natural state, 
containing new genetic material and becoming 
capable of degrading oil in its new form.  By contrast, 
the challenged patent in Funk Brothers was based on 
a naturally-­occurring phenomenon;; namely, the 
DELOLW\ RI FHUWDLQ ´LVRODWHGµEDFWHULD WR HIILFLHQWO\ IL[
nitrogen without inhibiting each other.  Even though 
the bacteria did not exist together naturally and even 
though their aggregate nitrogen-­fixing capability had 
been newly identified and had commercial utility, the 
Court invalidated the patent because the patent 
KROGHUGLG´QRWFUHDWH>D@VWDWHRILQKLELWLRQRURIQRQ-­
LQKLELWLRQ LQ WKH EDFWHULDµ   86 DW   7KH
Funk Brothers bacteria did not have markedly 
different characteristics because their qualities were 
the work of nature, not of the patentee.  Funk 
Brothers and Chakrabarty teach that the conditions 
of section 101 cannot be satisfied when compositions 
function as they would naturally, even when human 
ingenuity led to their packaging in a more useful 
form.      
These cases drew on principles laid out in 
American Fruit Growers, in which the Court also 
grappled with the change necessary to create a 
patentable invention.  The Court rejected the 
patenting of a fruit that had been treated with mold-­
UHVLVWDQWERUD[HYHQWKRXJKWKH´FRPSOHWHDUWLFOH LV
QRWIRXQGLQQDWXUHµDQGGHVSLWHLWV´WUHatment, labor 
DQGPDQLSXODWLRQµ  283 U.S. at 11-­12.  The Court 
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VDLG  ´7KHUHLVQRFKDQJH LQWKHQDPHDSSHDUDQFH
or general character of the fruit.  It remains a fresh 
orange fit only for the same beneficial uses as 
WKHUHWRIRUHµId. at 12.  Even though the treated fruit 
had enhanced functionality because it would not rot 
as quickly, the primary use of the fruit remained the 
same ² for human consumption ² and thus the 
FKHPLFDO WUHDWPHQW GLG QRW JLYH LW D ´GLVWLQFWLYH
QDPHFKDUDFWHURUXVHµId. 
Under this precedent, the patents on isolated 
DNA improperly claim products and laws of nature.  
Isolated DNA does not have markedly different 
characteristics from DNA in the body ² either in 
structure or function.  Only because isolated DNA is 
not markedly different can Myriad tell patients if 
they face an increased risk of breast or ovarian 
cancer after performing diagnostic testing. 
7KH FODLPV· GHILQLWLRQ RI WKH SDWHQWHG '1$
based on biological characteristics, and the sheer 
number of molecules that are accordingly patented, 
provide key evidence that the claims reach products 
and laws of nature.  The patents define the claim 
terms so broadly that they include the BRCA1 and 
%5&$JHQHVRIHYHU\SHUVRQ7KH\UHDFK´DOOIRUPV
RI PXWDWLRQVµ RU YDULDWLRQV  3DWHQW · -­32, 
2J.A. 751.  They reach any DNA if it is as little as 
60% similar to the specified DNA and any DNA that 
creates proteins as little as 30% similar to the 
VSHFLILHG SURWHLQV  3DWHQW ·  -$ 
3DWHQW · -­64, 2J.A. 757.   They reach all 
fragments of both the DNA and the proteins.  The 
claims also reach other forms of genetic material, 
LQFOXGLQJ ´51$ F'1$ JHQRPLF '1$ V\QWKHWLF




LQWHUYHQLQJ VHTXHQFHV DQG UHJXODWRU\ HOHPHQWVµ
3DWHQW · -­40;; 2J.A. 755.  They reach DNA 
PRGLILHG E\ ´PHWK\ODWLRQµ RU RWKHU ELRFKHPLFDO RU
chemical modifications or not so modified.  Patent 
· -­67, 2J.A. 755;; see also Pet. App. 263a.  
7KXV ZKLOH 0\ULDG DVVHUWV WKDW LW KDV SDWHQWHG ´D
FRPSRVLWLRQµ LW KDV DFWXDOO\ SDWHQWHG KXQGUHGV RI
millions of compositions, most of which have as yet 
unidentified structures and functions, and all of 
which have been created by nature. 
Even without rHVRUWWRWKHSDWHQWV·GHILQLWLRQV
of the claim terms, the claim language itself reaches 
a huge number of compositions, based on their 
naturally-­occurring characteristics.  Claim 1 of 
3DWHQW·FRYHUV'1$WKDWFRGHVIRUDOOYHUVLRQVRI
the specified BRCA1 protein.  The claim does not 
specify a particular gene that Myriad created or 
identified, but instead reaches any form of the gene 
WKDWH[LVWVLQQDWXUH&ODLPRI3DWHQW·UHDFKHV
any isolated DNA coding for a mutated form of the 
BRCA2 polypeptide associated with susceptibility to 
cancer.  The claim does not specify any of the 
mutations that are covered by the claim, nor the type 
of cancer that might be associated with a mutated 
IRUP  &ODLPV  DQG  RI 3DWHQW ¶ FODLP '1$
sequences with as few as 15 nucleotide bases;; small 
DNA segments sharing 15 nucleotide bases of the 
BRCA1 gene appear throughout the human genome.  
1J.A. 631-­34, 661-­68.  The claims do not seek to claim 
one or more specific genes (or even gene fragments) 
intentionally created and made different by the 
inventor, but instead claim every one of the segments 
that occur in nature. 
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Three of the four lower court judges correctly 
found that the structure of an isolated full-­length 
gene is not markedly different from DNA in the body.  
Pet. App. 85a-­86a, 102a-­13a, 333a-­44a.  They 
UHMHFWHG 0\ULDG·V DUJXPHQW WKDW VHSDUDWLQJ D JHQH
from other parts of the body with which it is bound 
makes it structurally different.  In so holding, they 
LPSOLFLWO\ RU H[SOLFLWO\ DFNQRZOHGJHG WKDW 0\ULDG·V
argument improperly confuses chromatin, the 
proteins and other elements attached to DNA in a 
cell, with the DNA itself.  See 85a-­86a, 108a, 337a-­
38a. 
Judge Lourie found the structure was 
markedly different when a chromosome was split 
into constituent pieces such as genes.  Pet. App. 51a-­
52a.  As noted, he was simply wrong that fragments 
of chromosomes, with broken covalent bonds, do not 
appear in the body.  See infra, p.10-­11 n. 2.  He was 
simply wrong in his implicit view that scientists 
isolating genes choose where to break covalent bonds.  
See infra, p. 11 n.3.  But even were he correct, the 
idea that a piece of nature is patentable by breaking 
it into its constituent parts is fundamentally 
erroneous.  Hydrogen separated from the oxygen to 
which it is bound in water is still a product of nature.   
Likewise, removing DNA from its natural 
environment does not automatically create 
´PDUNHGO\ GLIIHUHQW FKDUDFWHULVWLFVµ  0DQ\ QDWXUDO
products must be physically separated from their 
natural environments in order to be used by 
mankind, but under Funk Brothers, that is not 
sufficient to render them patentable.  The strains of 
bacteria in Funk Brothers ZHUH ´LVRODWHGµ UHPRYHG
from their natural environment, and aggregated so 
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as to more efficiently fix nitrogen without inhibiting 
each other.  333 U.S. at 129-­30.  Nevertheless, they 
could not be patented.  Id. at 132.   
Judge Lourie focused narrowly on minor 
chemical changes incidental to isolation and viewed 
'1$·V IXQFWLRQDO FKDUDFWHULVWLFV DV LUUHOHYDQW HYHQ
WKRXJK '1$·V IXQFWLRQ LV LQKHUHQW LQ WKH FODLPV
3HW $SS D  ´:H UHFRJQL]H WKDW ELRORJLVWV PD\
think of molecules in terms of their uses, but genes 
are in fact materials having a chemical nature and, 
as such, are best described in patents by their 
VWUXFWXUHVUDWKHU WKDQE\ WKHLU IXQFWLRQVµ '1$LV
foremost an informational molecule, embodying the 
genetic code.  Pet. App. 259a-­60a, 334a-­43a;; 1J.A. 58-­
59, 130-­33, 135-­136, 232, 234-­35, 561-­62, 649-­50, 
680-­  ´7RGD\ WKH LGHD WKDW '1$ FDUULHV JHQHWLF
information in its long chain of nucleotides is so 
fundamental to biological thought that it is 
sometimes difficult to realize the enormous 
LQWHOOHFWXDOJDS WKDW LW ILOOHGµ %UXFH$OEHUWV HW DO
Molecular Biology of the Cell 98 (3d ed. 1994) (also 
QRWLQJ ´'1$ LV UHODWLYHO\ LQHUW FKHPLFDOO\µ id. at 
104).  Other chemicals in the human body remain the 
same, albeit in different quantities, from person to 
person.  For example, H2O, HOH and OH2 all 
describe and represent the exact same water 
molecule;; the nucleotide sequences of TAA, ATA and 
AAT encode entirely different amino acids.  1J.A. 
676.  Accordingly, the patents describe DNA by its 
nucleotide sequence, not the sugars and phosphates 
that make up its backbone, or the covalent bonds in 
between.  1J.A. 661-­73, 676.  There is no reading of 
the patent claims, case law, or science that justifies 
privileging the breaking of covalent bonds over all 
else (including other types of bonds and any analysis 
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of function) in making patent eligibility 
determinations. 
Turning to an analysis of functional 
differences between isolated genes and unisolated 
ones, Myriad has argued that genes are patentable 
because they can be used outside the body in ways 
they cannot be used inside the body.  This argument 
not only ignores the breadth of the challenged claims, 
which are not limited to any such new uses, but it 
also fundamentally misunderstands the product of 
nature doctrine.  Gold does not become patentable 
once taken out of a stream because it can be used in 
jewelry;; kidneys do not become patentable once 
taken out of a body because they can be 
transplanted.  Put another way, one potential use 
unspecified by the patent claim does not justify a 
patent on the product of nature itself and all uses of 
it.  See Mayo, 132 S. Ct. at 1293-­94. 
None of the nine claims challenged is limited 
to a particular use or function.9  Indeed, the two key 
FODLPVWKHPVHOYHVGHILQH´LVRODWHG'1$µDFFRUGLQJWR
a naturally-­occurring function ² QDPHO\´FRGLQJIRUµ
                                                 
9 :KLOHFODLPVDQGRI·UHDFKYHU\VKRUWJHne fragments, 
they reach full-­length genes as well;; both include DNA of at 
least 15 nucleotides.  Thus, the discussion by Judge Moore 
analyzing the uses of gene fragments as primers and probes, 
App. at 82a-­83a, must be rejected as dicta.  None of the claims 
is limited to gene fragments, and none is limited to uses as 
primers and probes.  See infra, pp. 11-­17.  And as a majority of 
the Federal Circuit and the district court held, scientists cannot 
use full-­length genes as primers because they are too long.  Pet. 
App. 85a, 115a;; 1J.A. 673-­74.  Similarly, full-­length genes 
cannot be used as probes unless altered by a process called 




a naturally-­occurring polypeptide.  See, e.g., Pet. App. 
D&ODLPRI3DWHQW·%HFDXVHWKLVEOXHSULQW
is the essential characteristic of DNA and remains 
WKH VDPH EHIRUH DQG DIWHU LVRODWLRQ ´LVRODWHGµ '1$
does not have markedly different characteristics from 
any found in nature, nor a distinctive name, 
character, or use.  Both are DNA, the protein coded 
for by each is the same, and their use in storing and 
WUDQVPLWWLQJLQIRUPDWLRQDERXWDSHUVRQ·VKHUHGLW\LV
identical.  Indeed, classic experiments demonstrated 
that isolated DNA, once introduced into other cells 
and incorporated into chromosomes, would perform 
the very same function as it did while in the body.  
1J.A. 650-­7KHLVRODWHG'1$PROHFXOHV´VHUYHWKH
ends nature originally provided and act quite 
independently RI DQ\ HIIRUW RI WKH SDWHQWHHµ  Funk 
Bros., 333 U.S. at 131.  As the district court held, 
´'1$ DQG LQ SDUWLFXODU WKH RUGHULQJ RI LWV
nucleotides, therefore serves as the physical 
embodiment of laws of nature ² those that define the 
FRQVWUXFWLRQ RI WKH KXPDQ ERG\µ  3HW $SS D
Only because this most basic function of DNA is not 
changed by isolation can Myriad perform its 
diagnostic tests and tell patients if they are at an 
increased risk of breast or ovarian cancer. 
B.   The Challenged Claims Are Not 
Based On Any Inventive Concept 
But Instead Claim Products And 
Laws Of Nature. 
In Mayo, the Court highlighted another 
method of determining patent-­eligibility found in its 
precedent ² whether the patent is based on an 
´LQYHQWLYHFRQFHSWµ6&Wat 1294, 1297.  Mayo 
DVNHG GRHV WKH FODLP DULVH IURP DQ ´¶LQYHQWLYH
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FRQFHSW· VXIILFLHQW WR HQVXUH WKDW WKH SDWHQW LQ
practice amounts to significantly more than a patent 
XSRQ WKH QDWXUDO ODZ LWVHOIµ"  Id. at 1294.  Does it 
´DGGHQRXJKµRU´VLPSO\DSSHQG>] conventional steps, 
specified at a high level of generality, to laws of 
QDWXUH>RU@QDWXUDOSKHQRPHQDµ"Id. at 1300. 
Mayo and Funk Brothers elaborate on the 
inventive concept analysis.  In Mayo, the Court found 
that the claims were not inventive, despite 
transformations that occurred during the 
administration of a drug and determination of 
metabolite levels, because nothing of significance was 
added to the law of nature ² WKHSDWLHQW·VUHVSRQVHWR
a drug.  The steps of administering a drug and 
determining metabolite levels were routine, 
conventional science.  Id. at 1297-­98.  The only 
addition in the patent claim was the identification by 
Prometheus of the metabolite levels that indicate 
drug efficacy.   Id. at 1297.  The claims simply 
´LQIRUP D UHOHYDQW DXGLHQFH DERXW FHUWDLQ ODZV RI
QDWXUHµId. at 1298.  In Funk Brothers, even though 
the patentee arguably advanced the field because his 
FRPELQDWLRQ RI EDFWHULD ´FRQWULEXWHG XWLOLW\ DQG
economy to the manufacture and distribution of 
FRPPHUFLDO LQRFXODQWVµ  86 DW -­31, the 
Court found that Section 101 was not satisfied.  The 
only addition by the patentee was the discovery of 
WKHQDWXUDOTXDOLWLHVRIWKHEDFWHULD  ´>7@KHUHLVQR
invention here unless the discovery that certain 
strains of the several species of these bacteria are 
non-­inhibitive and may thus be safely mixed is 
invention.  But we cannot so hold without allowing a 
patent to issue on one of the ancient secrets of nature 
QRZGLVFORVHGµId. at 132.  
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Myriad identified the naturally-­existing gene, 
which embodies the natural law that some naturally-­
RFFXUULQJPXWDWLRQVRIWKDWJHQHLQFUHDVHDZRPDQ·V
risk of breast and ovarian cancer.  Myriad isolated 
those genes, but isolation of DNA was a well-­known 
technique at the time these patents were sought, and 
continues to be a routine, conventional preparatory 
step for using human genes in research and clinical 
practice.  1J.A. 642-­43, 689.  The only addition of the 
´LVRODWHGµ '1$ FODLPV WR WKH SURJUHVV RI VFLHQFH LV
disclosure of a natural genetic sequence created by a 
natural law itself ² the fact that this sequence of 
DNA encodes for the BRCA protein and embodies 
informatLRQ LPSRUWDQW IRU XQGHUVWDQGLQJ D SHUVRQ·V
heredity and disease susceptibility.  The claimed 
FRPSRVLWLRQ LV D GLVFRYHU\ RI QDWXUH·V KDQGLZRUN
Chakrabarty, 447 U.S. at 310.  And while isolation is 
needed to use the sequence to identify the law of 
QDWXUH LQ D SDUWLFXODU SHUVRQ·V JHQH WKH JHQHWLF
VHTXHQFH ´LWVHOI H[LVWV LQ SULQFLSOH DSDUW IURP DQ\
KXPDQDFWLRQµ Mayo, 132 S. Ct. at 1297.  Just as 
administering a drug triggered manifestation of a 
person·V QDWXUDOPHWDEROLVP RI WKLRSXULQH LQMayo, 
LVRODWLQJ '1$ PHUHO\ PDNHV YLVLEOH D SHUVRQ·V
inherited genetic makeup. 
Perhaps the most obvious illustration of the 
ODFN RI DQ ´LQYHQWLYHµ FRQFHSW LQ0\ULDG·V FODLPV LV
FODLP  RI 3DWHQW ·   ,W UHDFKHV DQ\ LVRODWHG
%5&$'1$WKDWLV´DVVRFLDWHGZLWKDVXVFHSWLELOLW\
WRFDQFHUµ 3HW$SSD 0\ULDGKDVLGHQWLILHGD
gene in the body, but now claims any mutations 
created by nature that are found by anyone at any 
WLPH DQG DUH ´DVVRFLDWHG ZLWK D VXVFHSWLELOLW\ WR
FDQFHUµ  0\ULDG VXUHO\ FDQQRW FODLP WR KDYH
invented mutations identified by others. 
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In some ways, the inventive concept analysis 
RYHUODSVZLWKWKH´PDUNHGO\GLIIHUHQWFKDUDFWHULVWLFV
from any foXQGLQQDWXUHµVWDQGDUGGLVFXVVHGsupra, 
particularly when compositions of matter are at 
issue.  The focus on inventive concept is helpful, 
however, in explaining the difference between 
novelty and utility inquiries and the Section 101 
exceptions, which lower courts sometimes have 
blurred.  The inventive concept required to satisfy 
Section 101 depends on determining whether what 
WKH LQYHQWRUKDV´DGGHGµWRWKH ILHOG LVDSURGXFWRU
law of nature, or whether the inventor has 
transformed it into more.  Although it is possible that 
the novelty or utility criteria would be satisfied by 
the new discovery of a natural phenomenon or a 
discovery of its utility, Section 101 per se precludes 
such patents.  See Mayo, 132 S. Ct. at 1303-­04.  See 
also In re Marden, 47 F.2d 958, 959 (C.C.P.A. 1931) 
UHMHFWLQJ SDWHQW RQ SXUH YDQDGLXP EHFDXVH ´SXUH
vanadium is not new in the inventive sense, and, it 
being a product of nature, no one is entitled to a 
PRQRSRO\RIWKHVDPHµ 
Other cases apply the inventive concept 
analysis and offer further support for the invalidity 
of these claims.  The Third Circuit held that a patent 
applicant named Coolidge could not patent 
´>V@XEVWDQWLDOO\ SXUH WXQJVWHQ KDYLQJ GXFWLOLW\ DQG
KLJK WHQVLOH VWUHQJWKµ GHVSLWH WKH VXSHULRULW\ RI
purified tungsten over its naturally-­occurring, brittle 
form.  Gen. Elec. Co. v. De Forest Radio Co., 28 F.2d 
641, 643 (3d Cir. 1928). 
Naturally we inquire who created pure 
tungsten.  Coolidge?  No.  It existed in 
nature and doubtless has existed there 
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for centuries. The fact that no one 
before Coolidge found it there does not 
negative its origin or existence. 
Id. at 643.  General Electric confirms that courts 
must examine whether the composition and any 
characteristics specified in the claims were invented 
by the patentee or were the work of nature.  See also 
In re Marden, 47 F.2d 957 (C.C.P.A. 1931) (rejecting 
patent on purified uranium);; In re Marden, 47 F.2d 
at 958 (rejecting patent on purified vanadium);; In re 
Merz, 97 F.2d 599 (C.C.P.A. 1936) (rejecting patent 
on purified ultramarine).  In the early case of Ex 
Parte Latimer, the Patent Commissioner rejected a 
patent on fibers extracted from pine needles that 
could more easily be spun and woven.  1889 Dec. 
&RPP·U 3DW    7KH DSplicant did not 
invent the length, strength, or fineness of the fibers;; 
´>Q@DWXUHPDGHWKHPVRDQGQRWWKHSURFHVVE\ZKLFK
WKH\ DUH WDNHQ IURP WKH OHDI RU WKH QHHGOHµ  Id. at 
125.  Cf. Am. Wood Paper Co. v. Fibre Disintegrating 
Co., 90 U.S. 566, 593-­94 (1874) (finding that cellulose 
derived from wood and useful for making paper was 
unpatentable).   
Myriad did not invent the isolated DNA.  
Myriad did not invent any of the characteristics of 
DNA that are incidental to its isolation.  Myriad did 
not invent the length, composition, or function of the 
BRCA1 or BRCA2 genes;; human biology determined 
these qualities of the two genes.  Pet. App. 106a-­07a, 




C.   The Challenged Claims Preempt 
Uses Of Products And Laws Of 
Nature. 
As Mayo reaffirmed, a key aspect of the 
product or law of nature analysis turns on whether 
the patent preempts use of the laws and products of 
QDWXUH  'RHV WKH SDWHQW ´ULVN GLVSURSRUWLRQDWHO\
tying up the use of the underlying natural laws, 
inhibiting their use in the making of further 
GLVFRYHULHVµ"6&WDW3DWHQWVRQQDWXUDO
phenomena present roadblocks to scientific inquiry 
and innovation, thus running counter to the 
constitutional mandate that patenWV ´SURPRWH WKH
SURJUHVV RI VFLHQFHµ  86 &RQVW DUW ,   FO 
Chakrabarty86DW  ´>0@RQRSROL]DWLRQRI
[basic scientific and technological] tools through the 
grant of a patent might tend to impede innovation 
UDWKHUWKDQLWZRXOGWHQGWRSURPRWHLWµMayo, 132 
6&W DW  7KXV WKH&RXUW·V SUHFHGHQWV ´ZDUQ
us against upholding patents that claim processes 
WKDW WRR EURDGO\ SUHHPSW WKH XVH RI D QDWXUDO ODZµ
Id. at 1294;; see also Bilski, 130 S. Ct. at 3231 
´$OORZLQJ SHWLWLRQHUV WR SDWHQW ULVN KHGJLQJ ZRXOG
pre-­empt use of this approach in all fields, and would 
HIIHFWLYHO\JUDQWDPRQRSRO\RYHUDQDEVWUDFWLGHDµ
Funk Bros., 86DW ´7KHTXDOLWLHVRI WKHVH
bacteria, like the heat of the sun, electricity, or the 
qualities of metals, are part of the storehouse of 
knowledge of all men. . . .  He who discovers a 
hitherto unknown phenomenon of nature has no 
claim to a PRQRSRO\RILWZKLFKWKHODZUHFRJQL]HVµ
2·5HLOO\ Y 0RUVH, 56 U.S. 62, 113 (1853) (The 
SDWHQWHH·V FODLP RQDQ\PDFKLQHU\ RU SURFHVV XVLQJ




 µ  7KH SUHHPSWLRQ LQTXLU\ XQGHU 6HFWLRQ  LV
determined by whether the patent claim authorizes 
the patentee to foreclose use of a product or law of 
nature.  Bilski, 130 S. Ct. at 3230.   
Claims on isolated DNA impermissibly 
preempt scientific and medical work, far beyond 
ZKDW0\ULDG·VFRQWULEXWLRQFDQ MXVWLI\10  See Mayo, 
132 S. Ct. at 1301.  The challenged claims cover all 
isolated forms of the naturally-­occurring genes, 
whether previously identified or not.  Some, like 
FODLP  RI · H[SUHVVO\ FODLP DGGLWLRQDO ODZV RI
nature (mutations that correlate with an increased 
risk of cancer), whether previously identified or not.  
All of the claims reach all uses of the genes in DNA, 
cDNA, or RNA form and all variants and fragments 
of the genes, including future uses not yet identified 
or technically achievable.  And because isolation is a 
necessary step in any serious study, research, or 
clinical or commercial use of the native DNA, the 
patents raise the same concerns about patenting a 
´EXLOGLQJ-­EORFNµ WKDW KDV SUHYLRXVO\ WURXEOHG WKH
Court.  See id. at 1303.  They also undermine the 
patent system by giving Myriad the right to any 
applications of isolated DNA without disclosing them 
or even having done the work to develop them.  See 
                                                 
10 :KLOH 0\ULDG·V ZRUN VKRXOG EH FUHGLWHG LW LV LPSRUWDQW WR
recognize that Myriad built upon the contributions of others.  
The process of isolation has been performed since as early as 
1869.  Pet. App. 255a n.3 (citing Ralf Dahm, Discovering DNA: 
Friedrich Miescher and the Early Years of Nucleic Acid 
Research, 122 Hum. Genetics 565 (2008)).  Other scientists 
discovered the locus of the BRCA1 gene years before Myriad 
sequenced it, and the federal government poured millions of 
dollars of funding into the search for the gene.  Pet. App. 272a-­
78a;; 1J.A. 247-­52. 
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Morse  86 DW  ´$QG LI KH FDQ VHFXUH WKH
exclusive use by his present patent he may vary it 
with every new discovery and development of the 
science, and need place no description of the new 
manner, process, or machinery, upon the records of 
the patent office . . . he claims an exclusive right to 
use a manner and process which he has not described 
and indeed had not invented, and therefore could not 
GHVFULEH ZKHQ KH REWDLQHG KLV SDWHQWµ  7KHVH
patents thus tie up all basic uses of the genes, 
´IRUHFORVH>LQJ@ PRUH IXWXUH LQQRYDWLRQ WKDQ WKH
underlying discovery could rHDVRQDEO\ MXVWLI\µ
Mayo, 132 S. Ct. at 1292.  
Because the patent claims reach all uses of the 
two human genes, Myriad has the authority to 
prevent all study of them.  When patent exclusivity 
extends to genes, science is seriously undermined.  
From the point of view of scientific 
research, human genetic sequences are 
as basic as you can get in terms of 
biological information.  They are as 
basic as the elements in the periodic 
table.  Patenting a gene or genetic 
sequence impedes scientific progress 
much the same way that patenting a 
naturally occurring element such as 
oxygen or gold would impede science. 
1J.A. 136 (statement of Nobel Prize-­winning biologist 
John Sulston);; see also 5HS RI WKH 6HF·\·V $GYLVRU\
&RPPRQ*HQHWLFV+HDOWKDQG6RF·\Gene Patents 
and Licensing Practices and their Impact on Patient 
Access to Genetic Tests 90 (Apr. 2010) (hereinafter 
´6$&*+6 5HSRUWµ 86 JHQH SDWHQW ODZ ´QRW Rnly 
threatens medical progress, it may also drive 
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YDOXDEOH JHQHWLF UHVHDUFKµ WR RWKHU FRXQWULHV
Francis S. Collins, The Language of Life:  DNA and 
the Revolution in Personalized Medicine 113 (2010) 
´7KH LQIRUPDWLRQ FRQWDLQHG LQ RXU VKDUHG
instruction book is so fundamental, and requires so 
much further research to understand its utility, that 
patenting it at the earliest stage is like putting up a 
whole lot of unnecessary toll booths on the road to 
GLVFRYHU\µ 1REHO3UL]H-­winning economist Joseph 




The effect of the patents has been to prevent 
and deter research.  Pet. App. 290a-­92a;; 1J.A. 144, 
257-­58, 623-­24, 708-­10, 714-­18.  The contested claims 
KDYH LQKLELWHG RWKHUV· ZLOOLQJQHVV WR HQJDJH LQ
research.  Over half of all labs surveyed as part of a 
government-­IXQGHG VWXG\ UHSRUWHG ´GHFLGLQJ QRW WR
develop a new clinical genetic test because of a gene 
SDWHQW RU OLFHQVHµ  1J.A. 144.  Another study found 
that 46% of surveyed geneticists felt that gene 
SDWHQWVKDG´GHOD\HGRU OLPLWHG WKHLU UHVHDUFKµ  Id.  
Some geneticists have felt a deep discomfort with 
conducting research on the BRCA genes because 
Myriad has prohibited them from disclosing genetic 
information to research subjects and sharply limited 
what it considers to be research.  1J.A. 59-­60;; 
Kimberly Blanton, Corporate Takeover Exploiting the 
U.S. Patent System, Boston Globe Mag., Feb. 24, 
2002, at 10.  And scholars looking closely at gene 
paWHQWV IRXQG WKH\ KDG ´SHUVLVWHQW QHJDWLYH HIIHFWV
RQ VXEVHTXHQW VFLHQWLILF UHVHDUFKµ  +HLGL /
Williams, Intellectual Property Rights and 
Innovation: Evidence from the Human Genome ii 
44 
 
(Nat'l Bureau of Econ. Research, Working Paper No. 




1J.A. 717-­18;; SACGHS Report at 63-­65;; Sam Kean, 
The Human Genome (Patent) Project, 331 Sci. 530 
(Feb. 4, 2011) (describing high barriers faced by 
biotechnology companies, including patents that are 
impossible to circumvent and the millions of dollars 
required to investigate relevant patent claims and to 
attempt to negotiate licensing deals).  
7KHVH SDWHQWV EDU DFFHVV WR SHRSOH·V JHQHWLF
information.  In Mayo, the Court suggested that a 
claim on a new drug would not raise the concern that 
LQYDOLGDWHG 3URPHWKHXV· SDWHQWV EHFDXVH DQRWKHU
company could develop another drug treating the 
same condition without infringing.  Mayo, 132 S. Ct. 
at 1302-­  ,Q FRQWUDVW WKH ´LVRODWHGµ '1$ FODLPV
are claims that do preempt future use of laws and 
products of nature because another entity cannot 
LQYHQW D JHQH WKDW HPERGLHV DSHUVRQ·V%5&$DQG
BRCA2 genetic information.  1J.A. 135-­36.  The 
claims that specifically claim DNA with as few as 15 
nucleotide bases preempt scientific work to an even 
greater extent, because sequences sharing at least 15 
nucleotides of the BRCA1 gene appear throughout 
the genome.  Pet. App. 226a-­27a;; 1J.A. 631-­35, 663-­
72. 
These patents preclude using the DNA for the 
development of drugs, instruments, and treatment 
methods.  Although the BRCA genetic testing Myriad 
offers is a useful application of isolated DNA, this 
value is dwarfed by the potential applications of 
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isolated DNA in new therapeutics, biomedical 
devices and instruments, and sequencing 
technologies.  See Jonathan D. Rockoff & Jess 
Bravin, Gene Patents Face Reckoning, Wall St. J., 
Dec. 30, 2012 (describing companies, even those 
which control gene patents, that believe ending gene 
SDWHQWVFRXOGEHD´SRVLWLYHGHYHORSPHQWEHFDXVH
it would open new opportunities to develop new 
testing services based on genHGLVFRYHULHVµ6RPHRI
these new applications might relate to breast and 
ovarian cancer, and some might not11;; yet, they all 
are precluded by the patents if they require using the 
BRCA DNA.  Myriad has used the challenged claims 
to prevent clinical testing of these genes by any other 
lab, even when others could do so at lower cost, to 
confirm results, or to ensure testing quality.  Many 
women, upon obtaining results from Myriad, wish to 
get a second opinion before they make life-­changing 
medical decisions, such as obtaining or refraining 
from prophylactic surgery.  Women cannot obtain 
confirmatory testing through other labs except for 
one small set of mutations.  Pet. App. 288a-­89a;; 
SACGHS Report at 33-­34.  Myriad also prevents 
others from providing testing at a lower price, or for 
IUHH DQG RQO\ PLOOLRQ RI $PHULFD·V PLOOLRQ
people currently receive insurance coverage for their 
testing.  1J.A. 536.   
                                                 
11 The BRCA genes have been linked to other cancers, including 
prostate and pancreatic.  See, e.g., Srinath Sundararajan et al., 
The Relevance of BRCA Genetics to Prostate Cancer 
Pathogenesis and Treatment, 9 Clinical Advances in 
Hematology & Oncology 748 (2011);; Kathleen M. Murphy et al., 
Evaluation of Candidate Genes MAP2K4, MADH4, ACVR1B 
and BRCA2 in Familial Pancreatic Cancer: Deleterious BRCA2 
Mutations in 17%, 62 Cancer Res. 3789 (2002).  
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These claims give rise to the same concern 
expressed by this Court in Mayo regarding how 
SDWHQWV´Whreaten to inhibit the development of more 
UHILQHG WUHDWPHQW UHFRPPHQGDWLRQVµ Mayo, 132 S. 
&WDW7KH´LVRODWHGµ'1$FODLPVDOORZ0\ULDG
to dictate the standard of testing that is offered.  It is 
undisputed that for several years, Myriad was 
performing tests that did not identify all known 
mutations.  Women with mutations not detected by 
0\ULDG·VWHVWVZHUHDQGFRQWLQXHWREHJLYHQIDOVHO\
reassuring results.  1J.A. 61, 151, 210, 220-­21, 258;; 
Robert Langreth, Myriad Stymies Cancer Answers by 
Impeding Data Sharing, Bloomberg, Dec. 28, 2012.  
Indeed, Myriad continues to separate testing for 
large genetic rearrangements from its standard 
testing, even though national guidelines recommend 
WKDW SDWLHQWV UHFHLYH VXFK WHVWLQJ  1DW·O
Comprehensive Cancer Network, NCCN Clinical 
Practice Guidelines in Oncology:  Genetic/Familial 
High-­Risk Assessment: Breast and Ovarian HBOC-­2, 
MS-­14-­15 (2012)  0RUHRYHU 0\ULDG·V PRQRSRO\ RQ
the BRCA genes prevents other laboratories from 
including these genes when clinically assaying the 
over twenty genes now known to be associated with 
hereditary risk for breast and ovarian cancer or 
when using next generation testing methods.  See, 
e.g., Tom Walsh et al., Detection of Inherited 
Mutations for Breast and Ovarian Cancer Using 
Genomic Capture and Massively Parallel Sequencing, 
3URF1DW·O$FDG6FL  ;; Hilmi Ozcelik et al., 
Long-­Range PCR and Next-­Generation Sequencing of 
BRCA1 and BRCA2 in Breast Cancer, 14 J. 
Molecular Diagnostics 419, 467 (2012);; SACGHS 
Report at 39-­40;; see also 1J.A. 59-­60, 86-­91, 208-­11, 
219-­24, 623;; Fed. Cir. App. A2813. 
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The patents also have interfered with 
deepening our knowledge about these genes.  
Scientists routinely share information about the 
importance of particular genes and particular gene 
mutations.  1J.A. 137-­39.  Because the patents have 
authorized Myriad to maintain a monopoly on 
clinical testing, they have permitted Myriad to 
control a huge amount of data on the nature and 
significance of variants in the BRCA1 and BRCA2 
genes.  For the last several years, Myriad has refused 
to share that data with the scientific community and 
has no obligation to collaborate with others.  Pet. 
App. 289a-­93a;; 1J.A. 62, 91, 206-­09;; Andrew Pollack, 
Despite Gene Patent Victory, Myriad Genetics Faces 
Challenges, N.Y. Times, Aug. 24, 2011;; see also 1J.A. 
136-­39.  If additional labs could engage in testing, 
the scientific community would know considerably 
more, particularly about those alterations of the gene 
whose significance is not now known.  1J.A. 62, 113-­
14, 222-­23.  Through its patents, Myriad not only 
commands the law of nature that is embodied by the 
BRCA genes, but also the laws of nature relating to 
how the BRCA genes function in tandem with other 
genes and genetic factors and how the genes might 
be linked to diseases other than breast and ovarian 
cancer ² key scientific insights required for the 
development of personalized medicine.  1J.A. 138-­39.  
Despite Mayo·V concerns about the impact of 
patents on innovation, the Federal Circuit majority 
refused to consider how the patents preempt use of 
laws and products of nature, impeding clinical and 
scientific work.  Pet. App. 43a-­44a, 58a-­59a.  The 
wide-­ranging harmful impact of these patents has 
led the medical and scientific establishment, 
including the American Medical Association, the 
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American Society of Human Genetics, and patient 
advocacy groups, to oppose them. 
Because virtually every conceivable scientific 
use of DNA requires that it be isolated, and because 
the patents do not specify a single BRCA molecule or 
a single use of the DNA but instead cover all of them, 
the patents give exclusivity over the BRCA1 and 
BRCA2 genes itself, and their preemptive effect 
mandates a finding of invalidity.   
II.  cDNA IS NOT PATENTABLE SUBJECT 
MATTER. 
Although Myriad has never asserted that any 
of its claims are limited to cDNA, and Petitioners 
agree that none of the challenged claims is limited to 
cDNA, the Department of Justice (and Judges Lourie 
and Bryson of the Federal Circuit after remand) 
thought one or more claims were limited to cDNA.   
Pet. App. 47a n.9, 100a.  The judges and DOJ 
apparently relied on the description of the sequence 
OLVWHG LQ WKH SDWHQW·V WDEOH 3DWHQW · 2J.A. 779) 
rather than the definition of DNA as used in the 
SDWHQWFODLP3DWHQW·-­53, 2J.A. 755, 822. 
This Court need not and should not reach the 
question of the patentability of cDNA.  The 
FKDOOHQJHGFODLPVGHILQH´LVRODWHG'1$µWRLQFOXGHD 
variety of types of compositions including genomic 
DNA (DNA with coding and non-­coding regions) and 
cDNA (DNA with coding regions).  See, e.g., Patent 
· -­18, 19:51-­53, 2J.A. 755.  Thus, if the 
definitions of DNA that Myriad insisted upon in its 
patents are credited, as they must be, a ruling 
finding isolated DNA unpatentable would defeat all 
of the challenged claims.  
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If, however, the Court interprets any of the 
challenged claims to be limited to just cDNA and 
chooses to address the patent-­eligibility of cDNA, it 
should find that claims on cDNA impermissibly claim 
products and laws of nature. 
At the simplest level, cDNA is identical to 
DNA except the non-­coding regions have been 
removed.  Myriad does not decide which nucleotides 
to remove.  Nature dictates which are coding and 
which are not.  Thus, comparing the capital letters 
OLVWHG LQ SDWHQW · ),*  ZKLFK LV '1$ ZLWK
coding regions in capital letters and non-­coding 
regions in small letters) with SEQ ID. NO.1 reveals 
that they are identical.  2J.A. 738-­45.  They are not 
´PDUNHGO\ GLIIHUHQWµ LQ VWUXFWXUH RQO\ WKH SDUWV
nature has made seemingly unnecessary are 
removed.  If DNA is analogized to a newspaper, 
cDNA is the identical newspaper without the ads. 
F'1$ DQG '1$ DOVR DUH QRW ´PDUNHGO\
diIIHUHQWµLQIXQFWLRQ'HILQLWLRQDOO\WKH\HQFRGHWKH
same polypeptide/protein.  BRCA1 or BRCA2 cDNA 
´FRGHV IRUµ RU FUHDWHV WKH %5&$ RU %5&$
polypeptide. 
Equally importantly, the non-­coding regions 
are removed in the body by nature.  In the process of 
making a protein, the DNA is first converted into 
mRNA by a naturally-­occurring process.  mRNA is 
fundamentally DNA but does not contain the non-­
coding regions.12  Pet. App. 265a-­67a.  To go to cDNA, 
                                                 
12 It is admittedly more complicated.  As noted above, DNA 
consists of four nucleotides:  A, G, T, and C.  Pet. App. 257a.  
Each uniquely binds to (or connects with) a binding partner.  
Thus, A always binds to T and C always binds to G.  Pet. App. 
258a;; 1J.A. 234.  When mRNA is made in the cell, the 
50 
 
the mRNA is removed from the body and converted 
into cDNA by repeating the complementary binding 
process that nature has dictated to re-­create the 
coding regions of the original DNA.  Pet. App. 266a-­
69a.  Thus, if the DNA sequence was a GCGTAT, the 
mRNA sequence will be CGCUTU, and the cDNA 
sequence will once again be GCGTAT as it was in the 
original DNA.13 
There is no scientific or legal distinction 
between isolated genomic DNA and cDNA that 
warrants treating their patent eligibility differently.  
Their characters and functions are both dictated by 
nature, not the patentee, and therefore neither has 
´PDUNHGO\GLIIHUHQWFKDUDFWHULVWLFVIURPDQ\IRXQGLQ
QDWXUHµ7KHFULWLFDOGLIIHUHQFHH[FOXVLRQRIWKHQRQ-­
coding regions, is accomplished entirely within the 
cell, by natural processes, without any human 
interventioQ  F'1$ ´LV DQ H[DFW FRS\ RI RQH RI WKH
protein coding sequences encoded by the original 
genomic DNA . . . In this respect, cDNA contains the 
identical protein coding informational content as the 
'1$LQ WKHERG\   µ 3HW$SSD see also Pet. 
App. D ´QRW RQO\ DUH WKH FRGLQJ VHTXHQFHV
contained in the claimed DNA identical to those 
                                                                                                    
nucleotide in the DNA is replaced by its binding partner.  Pet. 
App. 15a, 266a.  Thus, if the DNA nucleotides are GCG, the 
mRNA nucleotides made by the body will be a CGC.  mRNA 
DOVR XWLOL]HV D FKHPLFDO FDOOHG XUDFLO 8 LQ SODFH RI '1$·V 7
which binds to A.  Pet. App. 15a, 266a.  These changes are 
analogous to the simplest of all codes, in which the letter A is 
always replaced by B and B by C.  The substance has not 
changed and the changes are made by the body.  Finally, mRNA 
has different endings from DNA, called untranslated regions. 




found in native DNA, the particular arrangement of 
those coding sequences is the result of the natural 
SKHQRPHQD RI 51$ VSOLFLQJµ  $V D UHVXOW F'1$
simply does not KDYH ´PDUNHGO\ GLIIHUHQW
FKDUDFWHULVWLFVIURPDQ\IRXQGLQQDWXUHµ 
Although cDNA is frequently created in the 
laboratory using the above-­described process, 
scientists have documented the existence of the 
BRCA1 pseudogene1, a segment of the BRCA1 
cDNA, in the human genome.  Pet. App. 268a;; 1J.A. 
658-­59, 674-­75.  A ruling that DNA is not patentable 
because it is a product of nature necessarily would 
require a ruling that pseudogenes (or cDNA) are not 
patentable for the same reason.    
Even though cDNA is generally made in the 
laboratory, that fact alone does not render it 
patentable subject matter.  The nucleotide sequence 
of cDNA is dictated by nature, not by the lab 
technician;; indeed, the technician does not even 
know the sequence beforehand.  And presumably, the 
fruit at issue in American Fruit Growers was not 
treated while still on the tree;; nor were the Funk 
strains of bacteria isolated and combined in their 
natural habitat.  Chakrabarty would not have 
presented a close question if the legal standard 
turned on whether the bacterium was created in the 
laboratory or in the wild.  The setting for the creation 
of the patented composition does not determine its 
patent eligibility.  Nor is the synthetic nature of the 
composition decisive.  In Cochrane v. Badische Anilin 
& Soda Fabrik, the Court held that an artificial 
version of a natural red dye called alizarine that was 
produced by manipulating another compound 
through acid, heat, water, or distillation could not be 
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patented.  111 U.S. 293, 311 (1884).  Although the 
artificial version was brighter than observed in 
nature and prepared through a new, man-­made 
process, it was unpatentable because of its similarity 
to the natural product.  That it was synthesized, 
rather than naturally-­occurring, did not make it a 
patentable composition of matter, though the process 
of synthesizing artificial alizarine could be patented.  
Id.  Lastly, the fact that cDNA does not include non-­
protein-­coding sequences found in DNA does not 
transform it into an invention.  As the Court said in 
American Fruit Growers´HYHU\FKDQJHLQDQDUWLFOH
LVWKHUHVXOWRI WUHDWPHQW ODERUDQGPDQLSXODWLRQµ
but the key question remains, is it no longer a 
product of nature?  283 U.S. at 12.   
There is no inventive concept in cDNA.  The 
process resulting in cDNA was known long before 
Myriad obtained its patents and is not before the 
Court.  1J.A. 675;; Jeffrey Ross et al., In Vitro 
Synthesis of DNA Complementary to Purified Rabbit 
Globin mRNA, 69 Proc. Nat. Acad. Sci. USA 264 
(1972).  cDNA is a composition whose structure and 
function is dictated by and created by nature.    
Lastly, patenting cDNA preempts use of a 
basic scientific tool that serves as the basis for many 
genetic discoveries.  For example, many genetic 
engineering experiments involve producing and 
tinkering with cDNA.  Any foreseeable innovations 
that apply genetic engineering techniques in 
developing new ways of repairing mutated genes 
would require utilizing cDNA.  cDNA is also the 
basis for RNA sequencing that is used to quantify 
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how a gene is functioning.14  Furthermore, cDNA is 
modified and used in the development of 
recombinant drugs or therapeutic proteins.  Finding 
ways to change cDNA to produce a more useful 
protein are true discoveries worthy of patent 
protection;; the baseline cDNA is not.  
*LYHQ F'1$·V ELRORJLFDO UHODWLRQVKLS WR
naturally-­occurring mRNA, its existence in the 
naturally-­occurring human genome, its creation 
based on the naturally-­occurring biological 
PDFKLQHU\ RI WKH FHOO DQG LWV VWDWXV DV D ´EDVLF
VFLHQWLILF DQG WHFKQRORJLFDO WRROµ F'1$ LV QRW
patentable subject matter.  
III. THE COURT SHOULD DECIDE THE 
PATENTABILITY OF HUMAN GENES 
WITHOUT REGARD TO INDUSTRY 
RELIANCE ON PATENT OFFICE 
PRACTICE. 
Judge Moore thought full-­length genes were 
not patentable subject matter but provided the 
critical vote upholding the challenged claims because 
the PTO has long approved patents on genes and 
LQGXVWU\KDVUHOLHGXSRQWKHP7KH372·VSUDFWLFHLV
largely irrelevant.  Were it not, it would be unusual, 
not routine, for courts to invalidate patents.  For 
example, roughly 37% of all patents challenged on 
obviousness grounds were held invalid.  See Univ. of 
Houston Law Center Inst. for Intell. Prop. & Info. 
                                                 
14 RNA analysis is distinct from genetic sequencing in 
measuring a different type of gene malfunction.  See, e.g., Gina 
Kolata, In Treatment for Leukemia, Glimpses of the Future, N.Y. 
Times, July 8, 2012, at A1 (describing how researchers found 
WKHFDXVHIRURQHRQFRORJLVW·Vleukemia using RNA sequencing).   
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Law, Full Calendar Year 2011 Report, http:// 
www.patstats.org/2011_Full_Year_Report.html.  
Moreover, the U.S. government, in the course of this 
litigation, has filed two briefs arguing that isolated 
DNA is not patentable. 
That WKH 372·V SUDFWLFH LV EDVHG RQ ZULWWHQ
guidelines is equally irrelevant.  The 2001 PTO 
Utility Examination Guidelines, 66 Fed. Reg. 1092 
(Jan. 5, 2001) are guidelines for patent examiners, 
not binding on this Court.  See Hill-­Rom Co., Inc. v. 
Kinetic Concepts, Inc., 209 F.3d 1337, 1341 n.* (Fed. 
Cir. 2000).  They are also remarkably free of any 
analysis of their rationale, simply stating that 
´LVRODWHGµJHQHVGRQRWH[LVWLQWKHERG\1RWRQO\LV
WKLV LQFRUUHFW EXW LW PLVDSSUHKHQGV WKLV &RXUW·V
analysis for distinguishing products or laws of nature 
from inventions.   
3HUKDSVPRUHWURXEOLQJLV-XGJH0RRUH·VYLHZ
WKDW SDWHQWHHV DWWDLQ ´DGYHUVH SRVVHVVLRQµ RQ
products or laws of nature, Pet. App. 119a, if 
industry has relied on them.  Presumably, industry 
relies on any issued patent.  But more importantly, 
this Court confronted and flatly rejected this 
argument in Mayo.  132 S. Ct. at 1304-­05 (referring 
to the industry reliance argument of Prometheus and 
´VHYHUDO DPLFLµ %ULHI IRU0\ULDG *HQHWLFV ,QF DV
Amicus Curiae Supporting Respondent, Mayo 
Collaborative Servs. v. Prometheus Labs., Inc., 132 S. 
Ct. 1289 (2012) (No. 10-­1150), 2011 WL 5373694.  
It is not for the Court to balance policy 
considerations and dole out special patent protection 
for DNA.  The Court stated that such special 
protection must be expressly required by Congress:   
´$QG ZH PXVt recognize the role of Congress in 
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crafting more finely tailored rules where necessary.  
We need not determine here whether, from a policy 
perspective, increased protection for discoveries of 
GLDJQRVWLFODZVRIQDWXUHLVGHVLUDEOHµMayo, 132 S. 
Ct. at 1305 (citations omitted).  The Bilski 
concurrence, approving the invalidation of a business 
method patent, similarly noted that Congress, not 
the Court, should select the policy that best serves 
the FRQVWLWXWLRQDO DLP ´>D@QG DEVHQW D GLVFHUQLEOH
signal from Congress, we proceed cautiously when 
dealing with patents that press on the limits of the 
¶VWDQGDUGZULWWHQLQWRWKHFRQVWLWXWLRQ·µ6&WDW
3253 (citation omitted);; see also Microsoft Corp. v. 
AT&T Corp. 550 U.S. 437, 458 (2007) ´>2@XU
SUHFHGHQW OHDGV XV WR OHDYH LQ &RQJUHVV· FRXUW WKH
patent-­protective determinDWLRQ $7	7 VHHNVµ Eli 
Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1998) 
(finding exemption from infringement where statute 
was ambiguous as to scope of exemption). 
It is not clear that Congress could 
constitutionally abolish the product or law of nature 
doctrine in whole or in part, but it has not done so 
with respect to human genes.  This Court should 
apply long-­standing doctrine without regard to PTO 
deference and industry reliance and find the 
challenged claims unpatentable. 
IV.  PATENT CLAIMS ON ISOLATED DNA 
ALSO VIOLATE THE FIRST 
AMENDMENT BECAUSE THEY AMOUNT 
TO A GRANT OF EXCLUSIVE CONTROL 
OVER A BODY OF KNOWLEDGE.   
The First Amendment limits the reach of 
intellectual property laws.  In copyright, where the 
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potential conflict is more obvious, this Court has 
suggested that doctrines, like the idea/expression 
distinction, that are incorporated into statute are 
required by the First Amendment.  Harper & Row 
Publishers, Inc. v. Nation Enters., 471 U.S. 539, 556 
(1985);; Eldred v. Ashcroft, 537 U.S. 186, 219 (2003).  
See also Salinger v. Colting, 641 F. Supp. 2d 250, 255 
(S.D.N.Y. 2009), UHY·GRQRWKHUJURXQGV, 607 F.3d 68 
(2d Cir. 2010);; Maxtone-­Graham v. Burtchaell, 631 F. 
Supp. 1432, 1435 (S.D.N.Y. 1986).  Although the 
section 101 doctrine prohibiting patenting of natural 
phenomena has not been described previously as 
compelled by the First Amendment, there can be 
little doubt that granting patents that give control 
over an entire body of knowledge would violate the 
)LUVW$PHQGPHQW,QGHHGWKH&RXUW·VFRQFHUQDERXW
tying up basic scientific and technological tools 
highlights the priority placed on preventing patents 
that impede scientific thought and innovation.  Mayo, 
132 S. Ct. at 1293;; see also Gary L. Francione, 
Experimentation and the Marketplace Theory of the 
First Amendment, 136 U. Pa. L. Rev. 417, 428 (1987). 
For a typical invention, such as a carburetor, 
others can examine how the new carburetor 
functions once the patent is published and develop a 
better carburetor using different materials or 
PHWKRGV  %\ FRQWUDVW LI ´LVRODWHGµ R[\JHQ ZHUH
patented, no one could invent a new oxygen, and no 
one could study how it reacts in numerous scientific 
FRQWH[WV ZLWKRXW WKH SDWHQWHH·V SHUPLVVLRQ
Similarly, once a human gene is patented, nobody 
can invent a new human gene, and nobody can access 
57 
 
that particular human genetic information.15  See 
1J.A. 63, 139.   Because patent claims on the isolated 
BRCA1 and BRCA2 DNA prevent access to each 
SHUVRQ·VJHQHtic information, and accordingly deprive 
scientists of the opportunity to examine and study 
the genes, they are fundamentally different from 
patents on carburetors.   
Indeed, rather than leading to a greater 
understanding or a better product, the patent claims 
challenged in this case exclude others from further 
work with naturally-­occurring genes.  E.g., 1J.A. 139, 
148, 152.  Myriad has used its exclusive authority to 
amass an enormous amount of information critical to 
the health of every American.  Myriad refuses to 
allow others to obtain the information themselves or 
to share the information with the medical and 
scientific communities.  The claims thus give entire 
control over a body of knowledge and over pure 
information to Myriad.  That, under the First 
Amendment, is impermissible.  See Ashcroft v. Free 
Speech Coal., 535 U.S. 234, 253 (2002) ´)LUVW
Amendment freedoms are most in danger when the 
government seeks to control thought or to justify its 
laws for that impermissible end.  The right to think 
LV WKHEHJLQQLQJRI IUHHGRP    µ;; see also John A. 
Robertson, 7KH 6FLHQWLVW·V 5LJKW WR 5HVHDUFK $
Constitutional Analysis, 51 S. Cal. L. Rev. 1203, 
1217-­18 (1977) FRQFOXGLQJ WKDW ´>L@I WKH ILUVW
amendment serves to protect free trade in the 
dissemination of ideas and information, it must also 
protect the necessary preconditions of speech, such 
                                                 
15 Genes with new sequences can be invented, of course, that 
have never existed in nature.  Those are not at issue here. 
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as the production of ideas and information through 
UHVHDUFKµ 
The serious constitutional violation raised by 
these patent claims provides an additional reason for 
the Court to construe the statute to find the claims 
invalid.  The district court found it unnecessary to 
reach the constitutional questions, invoking the 
doctrine of constitutional avoidance.  Pet. App. 357a.  
However, if the Court finds the claims valid under 
the statute, it should find them unconstitutional 

















 For the foregoing reasons, the patent claims 
should be held invalid.  
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